<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S022352342030115X</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112148</dc:identifier><eid>1-s2.0-S022352342030115X</eid><prism:doi>10.1016/j.ejmech.2020.112148</prism:doi><pii>S0223-5234(20)30115-X</pii><dc:title>Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>191</prism:volume><prism:startingPage>112148</prism:startingpage><prism:pageRange>112148</prism:pagerange><articleNumber>112148</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-04-01</prism:coverdate><prism:coverDisplayDate>1 April 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Shu, Lei</dc:creator><dc:creator>Chen, Chengjuan</dc:creator><dc:creator>Huan, Xueting</dc:creator><dc:creator>Huang, Hao</dc:creator><dc:creator>Wang, Manman</dc:creator><dc:creator>Zhang, Jianqiu</dc:creator><dc:creator>Yan, Yile</dc:creator><dc:creator>Liu, Jianming</dc:creator><dc:creator>Zhang, Tiantai</dc:creator><dc:creator>Zhang, Dayong</dc:creator><dc:description>
                  As non-receptor tyrosine kinases, Janus kinases (JAKs) have become an attractive target for the treatment of autoimmune diseases and cancers. JAKs play a pivotal role in innate immunity, inflammation, and hematopoiesis by mediating the signaling of numerous cytokines, growth factors, and interferons (IFNs). Selective inhibitors of a variety of JAK members are expected to inhibit pro-inflammatory cytokine-mediated inflammation and immune responses, while preventing targeting other subtypes of JAKs. In this work, poorly selective compounds based on 4- or 6-phenyl-pyrimidine derivatives have been improved to highly potent and selective compounds by designing a covalent binding tether, which attaches to the unique cysteine (Cys909) residue in JAK3. Compound 12 exhibited potent JAK3 inhibitory activity (IC50 = 1.7 nM) with an excellent selectivity profile when compared to the other JAK isoforms (>588-fold). In a cellular assay, compound 12 strongly inhibited JAK3-dependent signaling and T cell proliferation. Moreover, in vivo data revealed that compound 12 significantly suppressed oxazolone (OXZ)-induced delayed hypersensitivity responses in Balb/c mice. Compound 12 also displayed decent pharmacokinetic properties and was suitable for in vivo use. Taken together, these results indicated that compound 12 may be a promising tool compound as a selective JAK3 inhibitor for treating autoimmune diseases.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Autoimmune diseases</dcterms:subject><dcterms:subject>Covalent JAK3 inhibitors</dcterms:subject><dcterms:subject>Cys909</dcterms:subject><dcterms:subject>Janus kinase</dcterms:subject><dcterms:subject>4- or 6-phenyl-pyrimidine derivatives</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S022352342030115X" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S022352342030115X" rel="scidir"/></link></coredata><objects><object ref="fx50" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="14" size="713">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx50.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="619">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="fx69" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="622">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx69.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="382" height="229" size="15707">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="232" size="29593">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="14" size="759">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="619">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx66" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="717">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx66.jpg?httpAccept=%2A%2F%2A</object><object ref="fx40" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="822">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx40.jpg?httpAccept=%2A%2F%2A</object><object ref="fx56" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="821">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx56.jpg?httpAccept=%2A%2F%2A</object><object ref="fx48" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="26" size="846">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx48.jpg?httpAccept=%2A%2F%2A</object><object ref="fx59" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="566">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx59.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="330" height="130" size="9511">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx51" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="564">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx51.jpg?httpAccept=%2A%2F%2A</object><object ref="fx62" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="821">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx62.jpg?httpAccept=%2A%2F%2A</object><object ref="fx36" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="14" size="598">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx36.jpg?httpAccept=%2A%2F%2A</object><object ref="fx54" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="822">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx54.jpg?httpAccept=%2A%2F%2A</object><object ref="fx57" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="623">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx57.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="19" size="799">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx35" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="622">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx35.jpg?httpAccept=%2A%2F%2A</object><object ref="fx67" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="566">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx67.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="600" height="476" size="62168">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx39" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="31" size="773">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx39.jpg?httpAccept=%2A%2F%2A</object><object ref="fx58" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="718">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx58.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="37" height="14" size="595">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="523" height="353" size="34261">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx61" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="622">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx61.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="820">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="718">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx26.jpg?httpAccept=%2A%2F%2A</object><object ref="fx34" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="20" size="781">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx34.jpg?httpAccept=%2A%2F%2A</object><object ref="fx41" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="59" height="27" size="766">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx41.jpg?httpAccept=%2A%2F%2A</object><object ref="fx46" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="719">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx46.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="427" size="34944">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="567">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx29.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="19" size="779">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="14" size="761">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="177" size="31829">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="400" size="58276">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="393" size="80158">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="565">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx25.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="14" size="599">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="19" size="798">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="19" size="800">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="52" height="18" size="754">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx32.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="329" height="126" size="9269">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="fx47" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="63" height="27" size="826">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx47.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="205" size="36008">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="718">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx24.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="565">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx37" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="63" height="27" size="824">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx37.jpg?httpAccept=%2A%2F%2A</object><object ref="fx43" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="31" size="773">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx43.jpg?httpAccept=%2A%2F%2A</object><object ref="fx38" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="819">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx38.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="567">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx31.jpg?httpAccept=%2A%2F%2A</object><object ref="fx64" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="820">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx64.jpg?httpAccept=%2A%2F%2A</object><object ref="fx49" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="63" height="27" size="827">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx49.jpg?httpAccept=%2A%2F%2A</object><object ref="fx65" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="625">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx65.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="553" size="122081">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx53" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="624">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx53.jpg?httpAccept=%2A%2F%2A</object><object ref="fx52" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="718">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx52.jpg?httpAccept=%2A%2F%2A</object><object ref="fx68" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="720">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx68.jpg?httpAccept=%2A%2F%2A</object><object ref="fx45" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="59" height="27" size="768">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx45.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="14" size="598">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="26" size="906">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx30.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="21" size="623">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx27.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="565">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="14" size="759">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="14" size="760">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="28" size="785">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx28.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="28" size="787">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="19" size="796">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx42" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="720">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx42.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="57" height="21" size="820">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="fx60" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="719">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx60.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="528" height="160" size="16420">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="581" height="438" size="64991">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="27" size="938">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx44" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="15" size="718">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx44.jpg?httpAccept=%2A%2F%2A</object><object ref="fx55" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="566">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx55.jpg?httpAccept=%2A%2F%2A</object><object ref="fx63" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="567">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx63.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="21" size="567">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx33.jpg?httpAccept=%2A%2F%2A</object><object ref="fx50" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2674">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx50.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="95" size="1888">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="fx69" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1845">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx69.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="131" size="4721">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="4849">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2693">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="95" size="1898">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx23.sml?httpAccept=%2A%2F%2A</object><object ref="fx66" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2843">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx66.sml?httpAccept=%2A%2F%2A</object><object ref="fx40" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="3023">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx40.sml?httpAccept=%2A%2F%2A</object><object ref="fx56" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2973">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx56.sml?httpAccept=%2A%2F%2A</object><object ref="fx48" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="3896">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx48.sml?httpAccept=%2A%2F%2A</object><object ref="fx59" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="95" size="1645">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx59.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="86" size="3582">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx51" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="95" size="1648">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx51.sml?httpAccept=%2A%2F%2A</object><object ref="fx62" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2946">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx62.sml?httpAccept=%2A%2F%2A</object><object ref="fx36" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="61" size="1770">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx36.sml?httpAccept=%2A%2F%2A</object><object ref="fx54" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2971">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx54.sml?httpAccept=%2A%2F%2A</object><object ref="fx57" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1932">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx57.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="2866">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="fx35" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1892">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx35.sml?httpAccept=%2A%2F%2A</object><object ref="fx67" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="95" size="1679">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx67.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="164" size="6619">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx39" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="130" size="3527">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx39.sml?httpAccept=%2A%2F%2A</object><object ref="fx58" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2805">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx58.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="164" height="62" size="1719">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="148" size="6109">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx61" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1895">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx61.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2982">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="fx26" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2869">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx26.sml?httpAccept=%2A%2F%2A</object><object ref="fx34" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="85" size="3338">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx34.sml?httpAccept=%2A%2F%2A</object><object ref="fx41" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="100" size="2929">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx41.sml?httpAccept=%2A%2F%2A</object><object ref="fx46" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2843">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx46.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="214" height="164" size="5320">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx29" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="95" size="1684">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx29.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="77" size="3269">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2713">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="77" size="5681">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="151" size="9490">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="138" size="18564">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="94" size="1655">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx25.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="61" size="1753">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="2843">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="2823">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx32" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="77" size="3221">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx32.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="84" size="3652">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="fx47" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="2916">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx47.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="81" size="6493">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2810">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx24.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="95" size="1657">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx37" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="2943">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx37.sml?httpAccept=%2A%2F%2A</object><object ref="fx43" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="130" size="3594">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx43.sml?httpAccept=%2A%2F%2A</object><object ref="fx38" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2942">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx38.sml?httpAccept=%2A%2F%2A</object><object ref="fx31" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="95" size="1662">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx31.sml?httpAccept=%2A%2F%2A</object><object ref="fx64" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2964">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx64.sml?httpAccept=%2A%2F%2A</object><object ref="fx49" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="2956">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx49.sml?httpAccept=%2A%2F%2A</object><object ref="fx65" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1877">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx65.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="164" size="17547">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="fx53" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1892">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx53.sml?httpAccept=%2A%2F%2A</object><object ref="fx52" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2859">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx52.sml?httpAccept=%2A%2F%2A</object><object ref="fx68" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2810">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx68.sml?httpAccept=%2A%2F%2A</object><object ref="fx45" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="100" size="2913">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx45.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="61" size="1771">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx30" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="3817">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx30.sml?httpAccept=%2A%2F%2A</object><object ref="fx27" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="94" size="1899">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx27.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="95" size="1678">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2693">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2692">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx28" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="112" size="3256">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx28.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="3323">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="2813">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx42" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="59" size="2862">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx42.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2962">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="fx60" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2824">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx60.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="67" size="3257">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="217" height="164" size="13513">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="3820">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx44" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2865">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx44.sml?httpAccept=%2A%2F%2A</object><object ref="fx55" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="94" size="1649">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx55.sml?httpAccept=%2A%2F%2A</object><object ref="fx63" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="94" size="1678">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx63.sml?httpAccept=%2A%2F%2A</object><object ref="fx33" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="95" size="1675">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx33.sml?httpAccept=%2A%2F%2A</object><object ref="fx50" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="61" size="4023">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx50_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="95" size="3217">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx69" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3271">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx69_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1691" height="1013" size="122950">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="1026" size="223989">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="256" height="62" size="4022">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="95" size="3219">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx66" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4354">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx66_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx40" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4502">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx40_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx56" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4500">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx56_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx48" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="117" size="5359">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx48_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx59" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="95" size="2818">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx59_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1464" height="575" size="73193">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx51" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="95" size="2816">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx51_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx62" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4497">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx62_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx36" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="61" size="3088">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx36_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx54" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4502">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx54_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx57" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3270">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx57_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="259" height="84" size="4490">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx35" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3269">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx35_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx67" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="95" size="2814">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx67_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2657" height="2107" size="506551">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx39" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="236" height="140" size="4856">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx39_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx58" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4364">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx58_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="164" height="62" size="3119">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2318" height="1566" size="278773">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx61" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3272">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx61_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4498">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4367">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx26_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx34" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="92" size="4553">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx34_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx41" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="263" height="120" size="4576">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx41_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx46" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4360">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx46_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2461" height="1888" size="276759">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="95" size="2807">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx29_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="239" height="84" size="4334">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="256" height="62" size="4031">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="782" size="251353">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="1771" size="453654">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="1743" size="649596">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="162" height="94" size="2831">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="61" size="3102">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="259" height="84" size="4486">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="259" height="84" size="4494">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="234" height="82" size="4251">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx32_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1459" height="558" size="72218">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx47" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="282" height="120" size="4981">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx47_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="910" size="256677">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4363">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="162" height="95" size="2838">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx37" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="282" height="120" size="4980">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx37_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx43" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="236" height="140" size="4858">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx43_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx38" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4509">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx38_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="95" size="2812">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx31_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx64" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4500">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx64_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx49" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="282" height="120" size="4986">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx49_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx65" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3280">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx65_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="2449" size="1125108">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx53" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3277">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx53_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx52" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4367">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx52_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx68" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4365">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx68_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx45" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="263" height="120" size="4579">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx45_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="61" size="3105">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="242" height="117" size="5452">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx30_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="94" size="3272">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx27_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="162" height="95" size="2844">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="256" height="62" size="4024">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="256" height="62" size="4027">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="241" height="123" size="4634">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx28_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="243" height="125" size="4851">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="259" height="84" size="4505">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx42" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="68" size="4351">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx42_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="254" height="92" size="4499">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx60" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4360">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx60_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2338" height="710" size="128812">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2571" height="1939" size="483514">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="243" height="120" size="5490">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx44" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="69" size="4361">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx44_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx55" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="162" height="94" size="2830">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx55_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx63" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="162" height="94" size="2841">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx63_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="161" height="95" size="2815">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-fx33_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="9677312">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-mmc1.doc?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1340540">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342030115X-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85079643127</scopus-id><scopus-eid>2-s2.0-85079643127</scopus-eid><pubmed-id>32097841</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85079643127" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200216">2020-02-16</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200216">2020-02-16</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200222">2020-02-22</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200222">2020-02-22</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-08-22T00:43:00</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S022352342030115X</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30115-X</xocs:pii-formatted>
      <xocs:pii-unformatted>S022352342030115X</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112148</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00043</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210108">2021-01-08T12:35:46.97865Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200401</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1581846854">2020-02-16T09:54:14.097051Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>191</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>191</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 191</xocs:vol-iss-suppl-text>
      <xocs:sort-order>18</xocs:sort-order>
      <xocs:first-fp>112148</xocs:first-fp>
      <xocs:article-number>112148</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112148</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200401</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 April 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-04-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSYNTHESISPHARMACOLOGICALEVALUATION46PHENYLPYRIMIDINEDERIVATIVESNOVELSELECTIVEJANUSKINASE3INHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>SHU</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>L</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vitro enzymatic inhibitor activities</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell cytotoxicity evaluation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compounds on T cell proliferation <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>12</ce:bold> selectively inhibits JAK3-dependent signaling in live cells</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Kinase selectivity profiling of compound <ce:bold>12</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>12</ce:bold> covalently binds to JAK3 and irreversibly inhibits JAK3</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Pharmacokinetic property evaluation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vivo immunosuppressive activity</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.10.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>12</ce:bold> inhibited oxazolone-induced delayed type hypersensitivity reaction</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.10.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>12</ce:bold> inhibited dose-dependent OXZ-induced DTH responses</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental procedures</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry and chemical methods</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Chloro-6-(3-nitrophenyl)pyrimidine (<ce:bold>40</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Chloro-6-(4-nitrophenyl)pyrimidine (<ce:bold>43</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Chloro-4-(3-nitrophenyl)pyrimidine (<ce:bold>46</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Chloro-4-(4-nitrophenyl)pyrimidine (<ce:bold>49</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenyl)pyrimidin-2-amine (<ce:bold>41a</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-(3-Aminophenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (<ce:bold>42a</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>Tert</ce:italic>-butyl(2-((3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) amino)-2-oxoethyl)carbamate (<ce:bold>52a</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Amino-N-(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acetamide (<ce:bold>53a</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>1</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>2</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>3</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)acrylamide (<ce:bold>4</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.13</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)amino)pyrimidin- 4-yl)phenyl)acrylamide (<ce:bold>5</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.14</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>6</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.15</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>7</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.16</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.17</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.18</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>10</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.19</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>11</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.20</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.21</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)but-2-enam ide (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.22</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>15</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.23</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>17</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.24</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)but-2-enamide (<ce:bold>19</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.25</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)amino)pyrimidin -4-yl)phenyl)but-2-enami-de (<ce:bold>20</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.26</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>21</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.27</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-((3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)amino)-2-oxoethyl)acrylamide (<ce:bold>24</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.28</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-((3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)amino)-2-oxoethyl) but-2-enamide (<ce:bold>25</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.29</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-((3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)amino)-2- oxoethyl)acrylamide (<ce:bold>26</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.30</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-((3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)amino)-2- oxoethyl)but-2-enamide (<ce:bold>27</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.31</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(3-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>30</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.32</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>32</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.33</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>34</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.34</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>36</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.35</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>38</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.36</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)ace tamide (<ce:bold>14</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.37</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)acetamide (<ce:bold>16</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.38</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acetami de (<ce:bold>18</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.39</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(3-(6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)acetamide (<ce:bold>22</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.40</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(2-((3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) amino)-2-oxoethyl)acetamide (<ce:bold>23</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.41</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(2-((3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl) amino)-2-oxoethyl)acetamide (<ce:bold>28</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.42</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(2-((3-(6-((1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)<ce:italic>amino)pyrimidin-</ce:italic>4-yl<ce:italic>)phenyl)amino)-2-oxoethyl)acetamide (</ce:italic>
                     <ce:bold>
                        <ce:italic>29</ce:italic>
                     </ce:bold>
                     <ce:italic>)</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.43</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(3-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>31</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.44</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(4-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>33</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.45</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(4-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>35</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.46</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(4-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>37</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.47</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-2-yl)phenyl)acetamide (<ce:bold>39</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Bioactivity</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Mice</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Biochemical assays-JAK enzymatic inhibition assay (cell-free kinase activity assays)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>T cell isolation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell viability assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>T cell proliferation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Kinase selectivity profiling</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Time assay and dissociation kinetics of compound <ce:bold>12</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vivo pharmacokinetic study</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vivo efficacy studies</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Computational analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Statistics</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>GADINA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>499</xocs:ref-first-fp>
            <xocs:ref-last-lp>514</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MAVERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>378</xocs:ref-first-fp>
            <xocs:ref-last-lp>385</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>OSHEA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>GHORESCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>273</xocs:ref-first-fp>
            <xocs:ref-last-lp>287</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>KAUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1074</xocs:ref-first-fp>
            <xocs:ref-last-lp>1086</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>MALERICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>7454</xocs:ref-first-fp>
            <xocs:ref-last-lp>7457</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>FRIDMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5298</xocs:ref-first-fp>
            <xocs:ref-last-lp>5307</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>PARMENTIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>23</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>HAMAGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4971</xocs:ref-first-fp>
            <xocs:ref-last-lp>4983</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>CHANGELIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>875</xocs:ref-first-fp>
            <xocs:ref-last-lp>878</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib11a">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>8012</xocs:ref-first-fp>
            <xocs:ref-last-lp>8018</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib11b">
            <xocs:ref-normalized-surname>WILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>219</xocs:ref-first-fp>
            <xocs:ref-last-lp>232</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib11c">
            <xocs:ref-normalized-surname>DAVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1046</xocs:ref-first-fp>
            <xocs:ref-last-lp>1051</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib11d">
            <xocs:ref-normalized-surname>FORSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1335</xocs:ref-first-fp>
            <xocs:ref-last-lp>1340</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>KLUNDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1045</xocs:ref-first-fp>
            <xocs:ref-last-lp>1058</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>BIGGIOGGERO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>212595</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>RIVELLESE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2823</xocs:ref-first-fp>
            <xocs:ref-last-lp>2843</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>THORARENSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1971</xocs:ref-first-fp>
            <xocs:ref-last-lp>1993</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>TELLIEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>3442</xocs:ref-first-fp>
            <xocs:ref-last-lp>3451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>KAWAMURA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>6374</xocs:ref-first-fp>
            <xocs:ref-last-lp>6378</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>OSHEA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>555</xocs:ref-first-fp>
            <xocs:ref-last-lp>564</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>ROCHMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>480</xocs:ref-first-fp>
            <xocs:ref-last-lp>490</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>RUSSELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>797</xocs:ref-first-fp>
            <xocs:ref-last-lp>800</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>CLARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5023</xocs:ref-first-fp>
            <xocs:ref-last-lp>5038</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>LIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>315</xocs:ref-first-fp>
            <xocs:ref-last-lp>326</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6589</xocs:ref-first-fp>
            <xocs:ref-last-lp>6606</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1646</xocs:ref-first-fp>
            <xocs:ref-last-lp>1657</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>YIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4774</xocs:ref-first-fp>
            <xocs:ref-last-lp>4786</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>YIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1562</xocs:ref-first-fp>
            <xocs:ref-last-lp>1576</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>49</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>TYNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5232</xocs:ref-first-fp>
            <xocs:ref-last-lp>5240</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>111590</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>NUHAILY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>25</xocs:ref-first-fp>
            <xocs:ref-last-lp>36</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>FUJII</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>220</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>SHUX2020X112148</xocs:refkey3>
         <xocs:refkey4ai>SHUX2020X112148XL</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-02-22T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-02-22T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-02-19T07:52:52.673Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30115-X</xocs:pii-formatted>
         <xocs:pii-unformatted>S022352342030115X</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S022352342030115X</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112148</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-01-08T12:35:46.97865Z</xocs:timestamp>
         <xocs:cover-date-start>2020-04-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/MAIN/application/pdf/44715bfa1d4b0058d15945c519eea26d/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>5776333</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>18</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S022352342030115X-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/PREVIEW/image/png/27ff33d145fe7ee72822695c48fd7063/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>58496</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx50.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx50/DOWNSAMPLED/image/jpeg/85e165f77523b7b4aecb08a0a9837aab/fx50.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx50</xocs:file-basename>
               <xocs:filename>fx50.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>713</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx19/DOWNSAMPLED/image/jpeg/18a798eec6bd8d64cee11e369a17ec83/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>619</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx69.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx69/DOWNSAMPLED/image/jpeg/f89b500cbca2c11ca843dea4efaf4f6b/fx69.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx69</xocs:file-basename>
               <xocs:filename>fx69.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>622</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc1/DOWNSAMPLED/image/jpeg/cc4ecfb3ec5e69625868d739cc9d2154/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>15707</xocs:filesize>
               <xocs:pixel-height>229</xocs:pixel-height>
               <xocs:pixel-width>382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr6/DOWNSAMPLED/image/jpeg/1230cafda99389777e05512ff2f9bc32/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29593</xocs:filesize>
               <xocs:pixel-height>232</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx5/DOWNSAMPLED/image/jpeg/b3ba502e2d1fdb21082d5b907052d825/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>759</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx23/DOWNSAMPLED/image/jpeg/6140e1dfe9b3331fafd88ea0c2479882/fx23.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>619</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx66.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx66/DOWNSAMPLED/image/jpeg/946742393fded01d841e22adff09f865/fx66.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx66</xocs:file-basename>
               <xocs:filename>fx66.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>717</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx40.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx40/DOWNSAMPLED/image/jpeg/ded5db48339fca853dba4959b4691269/fx40.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>822</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx56.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx56/DOWNSAMPLED/image/jpeg/0bf01decbbbeda6ed4c8f01f0a6ffc6a/fx56.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx56</xocs:file-basename>
               <xocs:filename>fx56.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>821</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx48.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx48/DOWNSAMPLED/image/jpeg/91cd6defb680b623ff8d26f5e98a3b6e/fx48.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx48</xocs:file-basename>
               <xocs:filename>fx48.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>846</xocs:filesize>
               <xocs:pixel-height>26</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx59.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx59/DOWNSAMPLED/image/jpeg/248bc75cad43e0200f0692477759c165/fx59.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx59</xocs:file-basename>
               <xocs:filename>fx59.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>566</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx2/DOWNSAMPLED/image/jpeg/f300315faa46e1a17af4007c9b51e6c3/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9511</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>330</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx51.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx51/DOWNSAMPLED/image/jpeg/3a7338dd1ba757bf84b5fbfd672cb082/fx51.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx51</xocs:file-basename>
               <xocs:filename>fx51.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>564</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx62.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx62/DOWNSAMPLED/image/jpeg/dde49bc13fcee53832669018d3f4e5b3/fx62.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx62</xocs:file-basename>
               <xocs:filename>fx62.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>821</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx36.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx36/DOWNSAMPLED/image/jpeg/14cc988334f7bcb07f2ce4904f26f0be/fx36.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>598</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx54.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx54/DOWNSAMPLED/image/jpeg/dbafef68e53b632cf25b0d5461086e67/fx54.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx54</xocs:file-basename>
               <xocs:filename>fx54.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>822</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx57.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx57/DOWNSAMPLED/image/jpeg/3d4fe7294ae80fba2d8f1b23a73fe50f/fx57.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx57</xocs:file-basename>
               <xocs:filename>fx57.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>623</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx9/DOWNSAMPLED/image/jpeg/e24ef6f22d8eed5d38914120469e672a/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>799</xocs:filesize>
               <xocs:pixel-height>19</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx35.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx35/DOWNSAMPLED/image/jpeg/92128a090a993d5694f0c7d15f9eb2fc/fx35.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>622</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx67.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx67/DOWNSAMPLED/image/jpeg/b6433e0d3c6da2a8ba5770c557f8c8d1/fx67.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx67</xocs:file-basename>
               <xocs:filename>fx67.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>566</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr2/DOWNSAMPLED/image/jpeg/2245c8232a8ddb9a52f5fe789f8de45e/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>62168</xocs:filesize>
               <xocs:pixel-height>476</xocs:pixel-height>
               <xocs:pixel-width>600</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx39.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx39/DOWNSAMPLED/image/jpeg/966c906b94be248d5f47182ca0730348/fx39.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>773</xocs:filesize>
               <xocs:pixel-height>31</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx58.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx58/DOWNSAMPLED/image/jpeg/5df605b4256511f937423c798eb3bb53/fx58.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx58</xocs:file-basename>
               <xocs:filename>fx58.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>718</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx3/DOWNSAMPLED/image/jpeg/6127efb58aec7d5703d5e7a73ccd3f73/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>595</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>37</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr1/DOWNSAMPLED/image/jpeg/a42c656b4b3bd628e4d1811da5c1c4ae/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34261</xocs:filesize>
               <xocs:pixel-height>353</xocs:pixel-height>
               <xocs:pixel-width>523</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx61.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx61/DOWNSAMPLED/image/jpeg/d18bf877827e770b48e2c92b43632e3d/fx61.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx61</xocs:file-basename>
               <xocs:filename>fx61.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>622</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx20/DOWNSAMPLED/image/jpeg/3925ad81da2eb025f8cb6e4d1cfbefee/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>820</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx26.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx26/DOWNSAMPLED/image/jpeg/da5aa9f454d900802e63cb591aee4d35/fx26.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>718</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx34.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx34/DOWNSAMPLED/image/jpeg/8e5ade20bcea00174cd541e4e5022b5a/fx34.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>781</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx41.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx41/DOWNSAMPLED/image/jpeg/9b2139ce48ef0bf8d43bc4754b923ff8/fx41.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>766</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>59</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx46.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx46/DOWNSAMPLED/image/jpeg/002ed2e33bbcd537bdc03777f16e307c/fx46.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx46</xocs:file-basename>
               <xocs:filename>fx46.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>719</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc2/DOWNSAMPLED/image/jpeg/c994cc33473bf5ca17348680a4777a71/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34944</xocs:filesize>
               <xocs:pixel-height>427</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx29.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx29/DOWNSAMPLED/image/jpeg/f6f0e22aa1f0b70583a9f72bebf9492a/fx29.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>567</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx8/DOWNSAMPLED/image/jpeg/b0a5e7063ad2d89acc75bbc4dd1da09b/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>779</xocs:filesize>
               <xocs:pixel-height>19</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx14/DOWNSAMPLED/image/jpeg/560e480f3ca68e16ba9443ab6b53866a/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>761</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx1/DOWNSAMPLED/image/jpeg/f255de2ff031229b38da743337f2a7bb/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31829</xocs:filesize>
               <xocs:pixel-height>177</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr7/DOWNSAMPLED/image/jpeg/052d3b5d0f5b246aefee1a65a1036e6b/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58276</xocs:filesize>
               <xocs:pixel-height>400</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr3/DOWNSAMPLED/image/jpeg/7412815464873e72afd9e5ddbad5f216/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>80158</xocs:filesize>
               <xocs:pixel-height>393</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx25/DOWNSAMPLED/image/jpeg/74aa26063aaf0196d2ec5cf8f8734b28/fx25.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>565</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx18/DOWNSAMPLED/image/jpeg/84304faa84ac6fde1ed46d7f0066999b/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>599</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx4/DOWNSAMPLED/image/jpeg/49d8483561f24f113a03e44afd1b55f8/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>798</xocs:filesize>
               <xocs:pixel-height>19</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx13/DOWNSAMPLED/image/jpeg/2de16b7f2087a97956902a27549c8855/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>800</xocs:filesize>
               <xocs:pixel-height>19</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx32.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx32/DOWNSAMPLED/image/jpeg/46034d6f2548d94384392a4690874f5b/fx32.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>754</xocs:filesize>
               <xocs:pixel-height>18</xocs:pixel-height>
               <xocs:pixel-width>52</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx15/DOWNSAMPLED/image/jpeg/66ee1417472ff60baa7c8b95ec31c8db/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9269</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>329</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx47.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx47/DOWNSAMPLED/image/jpeg/18012271c25a910e55996cfc43ab90ef/fx47.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx47</xocs:file-basename>
               <xocs:filename>fx47.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>826</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>63</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr4/DOWNSAMPLED/image/jpeg/fb53be1d35a63bd6953c208e45e11dde/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36008</xocs:filesize>
               <xocs:pixel-height>205</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx24/DOWNSAMPLED/image/jpeg/acdd68a919508adc41f8807afaea25f6/fx24.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>718</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx17/DOWNSAMPLED/image/jpeg/7351d65664041d5f4f3c1c5fafdb1767/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>565</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx37.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx37/DOWNSAMPLED/image/jpeg/e0f79b80f6ca6b47134e998e27ac76a5/fx37.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>824</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>63</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx43.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx43/DOWNSAMPLED/image/jpeg/0fabcd6ef71348b6aee28bd1594cfec0/fx43.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>773</xocs:filesize>
               <xocs:pixel-height>31</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx38.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx38/DOWNSAMPLED/image/jpeg/79fd8782a8e39488ac030562b6001189/fx38.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>819</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx31.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx31/DOWNSAMPLED/image/jpeg/097f66ea0dbc27773b3c6c3594f09ce3/fx31.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>567</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx64.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx64/DOWNSAMPLED/image/jpeg/cd83c1bd388d1fc73f7644e220e73cba/fx64.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx64</xocs:file-basename>
               <xocs:filename>fx64.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>820</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx49.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx49/DOWNSAMPLED/image/jpeg/8239ecfddac6fd08bdf8869e740f7c44/fx49.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx49</xocs:file-basename>
               <xocs:filename>fx49.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>827</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>63</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx65.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx65/DOWNSAMPLED/image/jpeg/c89b5fe40a562ce90c0f6a9a102f1b2e/fx65.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx65</xocs:file-basename>
               <xocs:filename>fx65.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>625</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr8/DOWNSAMPLED/image/jpeg/83f8e151cd2e5dc74c049eb981ec36df/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>122081</xocs:filesize>
               <xocs:pixel-height>553</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx53.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx53/DOWNSAMPLED/image/jpeg/284d831b5b771522ff81a765aa7d6dfe/fx53.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx53</xocs:file-basename>
               <xocs:filename>fx53.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>624</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx52.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx52/DOWNSAMPLED/image/jpeg/3e5e7de21859d2a12f94778fe02f160e/fx52.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx52</xocs:file-basename>
               <xocs:filename>fx52.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>718</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx68.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx68/DOWNSAMPLED/image/jpeg/66c453b5e3a5134a6b0439893b5d5aa0/fx68.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx68</xocs:file-basename>
               <xocs:filename>fx68.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>720</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx45.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx45/DOWNSAMPLED/image/jpeg/6875bf9d9061ad01edbb0272e562cff3/fx45.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>768</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>59</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx16/DOWNSAMPLED/image/jpeg/00603eabb3645a535b77f2b1bca4b324/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>598</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx30.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx30/DOWNSAMPLED/image/jpeg/d00f5cf41b35eaa3325e6a5aff9e5d8e/fx30.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>906</xocs:filesize>
               <xocs:pixel-height>26</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx27.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx27/DOWNSAMPLED/image/jpeg/36514ea246d61111081b9e8e21b57b6f/fx27.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>623</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx21/DOWNSAMPLED/image/jpeg/873a2afdf569423eb713c622fcd189f4/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>565</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx12/DOWNSAMPLED/image/jpeg/76c38e05fe25a8e6413f74a9e87d1197/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>759</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx10/DOWNSAMPLED/image/jpeg/8a1e0aed35e6e4a5d1eb29a6ef102d53/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>760</xocs:filesize>
               <xocs:pixel-height>14</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx28.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx28/DOWNSAMPLED/image/jpeg/33f407936de95b6ea125a09dd25c211c/fx28.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>785</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx6/DOWNSAMPLED/image/jpeg/75df2d5ae2f4c5dde10965b2fe216c81/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>787</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx11/DOWNSAMPLED/image/jpeg/2b4bcc3a373ba293a15bb9efd8e339dc/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>796</xocs:filesize>
               <xocs:pixel-height>19</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx42.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx42/DOWNSAMPLED/image/jpeg/3530db03e68b2bac8015fb0bf6802ed4/fx42.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>720</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx22/DOWNSAMPLED/image/jpeg/44f7f6f68b428052e73aff0562367b56/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>820</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>57</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx60.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx60/DOWNSAMPLED/image/jpeg/5e41b5b5145503386a9eda59abeb0da5/fx60.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx60</xocs:file-basename>
               <xocs:filename>fx60.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>719</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc3/DOWNSAMPLED/image/jpeg/ddf205f658fddb6ca62593ecb43f639e/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>16420</xocs:filesize>
               <xocs:pixel-height>160</xocs:pixel-height>
               <xocs:pixel-width>528</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr5/DOWNSAMPLED/image/jpeg/c89f6602280a864ac5e7364103da120d/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64991</xocs:filesize>
               <xocs:pixel-height>438</xocs:pixel-height>
               <xocs:pixel-width>581</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx7/DOWNSAMPLED/image/jpeg/9e498cfd2c41f1ced257178ecf8b570e/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>938</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx44.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx44/DOWNSAMPLED/image/jpeg/49887aab17de3280ad97f9658898a3a2/fx44.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>718</xocs:filesize>
               <xocs:pixel-height>15</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx55.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx55/DOWNSAMPLED/image/jpeg/467fcfa9d88194205e71271760df5ba0/fx55.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx55</xocs:file-basename>
               <xocs:filename>fx55.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>566</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx63.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx63/DOWNSAMPLED/image/jpeg/a67206a065f0527f472c596529e3fafd/fx63.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx63</xocs:file-basename>
               <xocs:filename>fx63.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>567</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx33.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx33/DOWNSAMPLED/image/jpeg/11e09baa4fa2f44cc6256dd550563466/fx33.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>567</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx50.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx50/THUMBNAIL/image/gif/bfa1c5dc5102e0991fe3435f409ceb46/fx50.sml</xocs:ucs-locator>
               <xocs:file-basename>fx50</xocs:file-basename>
               <xocs:filename>fx50.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2674</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx19/THUMBNAIL/image/gif/b728c9c2850c73eeb4ce49ce77048207/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1888</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx69.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx69/THUMBNAIL/image/gif/c7d7da740136727f9ec3f33f852d525d/fx69.sml</xocs:ucs-locator>
               <xocs:file-basename>fx69</xocs:file-basename>
               <xocs:filename>fx69.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1845</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc1/THUMBNAIL/image/gif/df900a852e8ccfbc71037bd2d1c03c57/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4721</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr6/THUMBNAIL/image/gif/448a2fdf42f4e4bb74dbf68f1baa7faf/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4849</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx5/THUMBNAIL/image/gif/f41fef04c162ad33397701c29d37d6e5/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2693</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx23/THUMBNAIL/image/gif/5c5e6c400ddfc0c07955cb9ddd0825f9/fx23.sml</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1898</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx66.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx66/THUMBNAIL/image/gif/426d13348d30d716a436228dcf9edef8/fx66.sml</xocs:ucs-locator>
               <xocs:file-basename>fx66</xocs:file-basename>
               <xocs:filename>fx66.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2843</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx40.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx40/THUMBNAIL/image/gif/f16b8b92ba617837dc13b73ab5f4575a/fx40.sml</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3023</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx56.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx56/THUMBNAIL/image/gif/57bc564124e7ce7a030e57dba1a4b33e/fx56.sml</xocs:ucs-locator>
               <xocs:file-basename>fx56</xocs:file-basename>
               <xocs:filename>fx56.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2973</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx48.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx48/THUMBNAIL/image/gif/3dcad4d6e3110428c5e87e319ed2fde9/fx48.sml</xocs:ucs-locator>
               <xocs:file-basename>fx48</xocs:file-basename>
               <xocs:filename>fx48.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3896</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx59.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx59/THUMBNAIL/image/gif/bc3e5e804aadb901559684bdbf16c76d/fx59.sml</xocs:ucs-locator>
               <xocs:file-basename>fx59</xocs:file-basename>
               <xocs:filename>fx59.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1645</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx2/THUMBNAIL/image/gif/85eeab12e010d3ffbbcac002d0fbecc7/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3582</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx51.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx51/THUMBNAIL/image/gif/2d3cd7c660825d7488862775803cee24/fx51.sml</xocs:ucs-locator>
               <xocs:file-basename>fx51</xocs:file-basename>
               <xocs:filename>fx51.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1648</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx62.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx62/THUMBNAIL/image/gif/063a9eb1fb34e9fcbde6729aa8c0f1c0/fx62.sml</xocs:ucs-locator>
               <xocs:file-basename>fx62</xocs:file-basename>
               <xocs:filename>fx62.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2946</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx36.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx36/THUMBNAIL/image/gif/61fecf91e7c1e0c1de77da373e8ab41f/fx36.sml</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1770</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx54.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx54/THUMBNAIL/image/gif/012df887cc0b1ac139fd5a7ea7ac8032/fx54.sml</xocs:ucs-locator>
               <xocs:file-basename>fx54</xocs:file-basename>
               <xocs:filename>fx54.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2971</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx57.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx57/THUMBNAIL/image/gif/66709313009d33d1833c73e9853734b9/fx57.sml</xocs:ucs-locator>
               <xocs:file-basename>fx57</xocs:file-basename>
               <xocs:filename>fx57.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1932</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx9/THUMBNAIL/image/gif/aff345a9ca42d8e6b848f7da89b073a4/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2866</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx35.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx35/THUMBNAIL/image/gif/04b0179e81a5a73e226a59033bd3dac2/fx35.sml</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1892</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx67.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx67/THUMBNAIL/image/gif/dcc695a5018dad023c65cb3618f539c3/fx67.sml</xocs:ucs-locator>
               <xocs:file-basename>fx67</xocs:file-basename>
               <xocs:filename>fx67.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1679</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr2/THUMBNAIL/image/gif/cb26326b6b77f6ff235d120efc3d60f8/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6619</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx39.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx39/THUMBNAIL/image/gif/88dd908d34d61589a1d91fb63bcc7a9a/fx39.sml</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3527</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx58.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx58/THUMBNAIL/image/gif/37560eef443b37b53353d6926eb19adb/fx58.sml</xocs:ucs-locator>
               <xocs:file-basename>fx58</xocs:file-basename>
               <xocs:filename>fx58.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2805</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx3/THUMBNAIL/image/gif/9351c1d53925ff4470f8983190220f3d/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1719</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>164</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr1/THUMBNAIL/image/gif/e0366f98dc7becd575c3102d73a2d36d/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6109</xocs:filesize>
               <xocs:pixel-height>148</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx61.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx61/THUMBNAIL/image/gif/1b8c7726dce3cb104e5c7e1293e191e9/fx61.sml</xocs:ucs-locator>
               <xocs:file-basename>fx61</xocs:file-basename>
               <xocs:filename>fx61.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1895</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx20/THUMBNAIL/image/gif/e4dc1a2ee35014fe4a7d5c13253e42dc/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2982</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx26.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx26/THUMBNAIL/image/gif/ac9b7e67088f40be78aec158696fdecc/fx26.sml</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2869</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx34.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx34/THUMBNAIL/image/gif/45403675b8881d87a51ee6490fc5ce56/fx34.sml</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3338</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx41.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx41/THUMBNAIL/image/gif/ec03f684c735cfe31d83f7793cc6e657/fx41.sml</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2929</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx46.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx46/THUMBNAIL/image/gif/d99a3ceee8683beba5b77d67bdebcc98/fx46.sml</xocs:ucs-locator>
               <xocs:file-basename>fx46</xocs:file-basename>
               <xocs:filename>fx46.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2843</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc2/THUMBNAIL/image/gif/39b7cf74998e3c4718e817932db46c9c/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5320</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>214</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx29.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx29/THUMBNAIL/image/gif/43e68624436c906972b33f10d0a3fe77/fx29.sml</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1684</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx8/THUMBNAIL/image/gif/aba9a507614c244ceb26260b98cc0141/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3269</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx14/THUMBNAIL/image/gif/c074e87ec710f8c9ca9b1b07326d86d9/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2713</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx1/THUMBNAIL/image/gif/4fd937359f210cfa8d51a6da615d2a5f/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5681</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr7/THUMBNAIL/image/gif/f450c424b91956e5eb79a4775aa150b1/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9490</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr3/THUMBNAIL/image/gif/6541bf154307a4ad1840e35815a846a4/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18564</xocs:filesize>
               <xocs:pixel-height>138</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx25/THUMBNAIL/image/gif/7cb1e7a85defa6f16aba1f02a57740e2/fx25.sml</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1655</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx18/THUMBNAIL/image/gif/6291c760c2f7ce45e15b2b57db45f278/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1753</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx4/THUMBNAIL/image/gif/e9b9b61430c23d9572c84ebb6e653cd7/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2843</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx13/THUMBNAIL/image/gif/35ae26b860187c5ef9f4ab3ecbd185e9/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2823</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx32.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx32/THUMBNAIL/image/gif/5527082a355e797febb98b093d4b3baf/fx32.sml</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3221</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx15/THUMBNAIL/image/gif/35cd9f3a7c8d6c925d85068472653303/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3652</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx47.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx47/THUMBNAIL/image/gif/e63525353da7f9bc7168520a3dfe5b0f/fx47.sml</xocs:ucs-locator>
               <xocs:file-basename>fx47</xocs:file-basename>
               <xocs:filename>fx47.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2916</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr4/THUMBNAIL/image/gif/f4464feae1d782113e05b9556961991d/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6493</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx24/THUMBNAIL/image/gif/aad55fbd21b3fa23e795668fd66352a3/fx24.sml</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2810</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx17/THUMBNAIL/image/gif/c6ef9e718cdb863b5e1c28660be4bb53/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1657</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx37.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx37/THUMBNAIL/image/gif/8efd2e6cf7127559e4a15bd6a2e9dc69/fx37.sml</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2943</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx43.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx43/THUMBNAIL/image/gif/2cd58c893438c40dc2d2c41ff09b0d0e/fx43.sml</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3594</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx38.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx38/THUMBNAIL/image/gif/1d8dea202bfdbe9a9c1d0a9d6e69a061/fx38.sml</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2942</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx31.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx31/THUMBNAIL/image/gif/c47383d81440745314e829da9401ea30/fx31.sml</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1662</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx64.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx64/THUMBNAIL/image/gif/4f9b315f8bc622490fa0ced93262360d/fx64.sml</xocs:ucs-locator>
               <xocs:file-basename>fx64</xocs:file-basename>
               <xocs:filename>fx64.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2964</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx49.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx49/THUMBNAIL/image/gif/999ff10dc74bb1c0c38cf22bb8295784/fx49.sml</xocs:ucs-locator>
               <xocs:file-basename>fx49</xocs:file-basename>
               <xocs:filename>fx49.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2956</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx65.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx65/THUMBNAIL/image/gif/89f8b7349a0d1f27a4dc8fc8ff19f4bf/fx65.sml</xocs:ucs-locator>
               <xocs:file-basename>fx65</xocs:file-basename>
               <xocs:filename>fx65.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1877</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr8/THUMBNAIL/image/gif/d74b4e7e076bfb1bc935c45eff359657/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17547</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx53.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx53/THUMBNAIL/image/gif/4718f202f041148d0136c88e4d996c89/fx53.sml</xocs:ucs-locator>
               <xocs:file-basename>fx53</xocs:file-basename>
               <xocs:filename>fx53.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1892</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx52.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx52/THUMBNAIL/image/gif/5b9dda8163c03be778835d3d57c9e66a/fx52.sml</xocs:ucs-locator>
               <xocs:file-basename>fx52</xocs:file-basename>
               <xocs:filename>fx52.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2859</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx68.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx68/THUMBNAIL/image/gif/b701e38b2d39bc3ef1876e0308b5717c/fx68.sml</xocs:ucs-locator>
               <xocs:file-basename>fx68</xocs:file-basename>
               <xocs:filename>fx68.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2810</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx45.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx45/THUMBNAIL/image/gif/d1e298a4cbcb8bf31b0be39eff49f4f4/fx45.sml</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2913</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx16/THUMBNAIL/image/gif/8121f7bfa44d6d6f2a44393e30c29bc1/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1771</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx30.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx30/THUMBNAIL/image/gif/1af5a60e89b8013597bb7f5a26a08061/fx30.sml</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3817</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx27.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx27/THUMBNAIL/image/gif/aba91022440efdb4257c04c6018fd5f0/fx27.sml</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1899</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx21/THUMBNAIL/image/gif/bdfedcfaedeeafd2f8115b90c2e922d8/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1678</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx12/THUMBNAIL/image/gif/9b37a2356097eb940ed64282fce78003/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2693</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx10/THUMBNAIL/image/gif/f03879799d5f05a628d32a0f61f70d7e/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2692</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx28.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx28/THUMBNAIL/image/gif/6d279b3ec081dcbc33dd81a7327aae9b/fx28.sml</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3256</xocs:filesize>
               <xocs:pixel-height>112</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx6/THUMBNAIL/image/gif/aea2ff9907cd756b88cafe5a78c02630/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3323</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx11/THUMBNAIL/image/gif/9ed47699531f3b94286ebc33b3dac9f9/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2813</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx42.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx42/THUMBNAIL/image/gif/d52fe99f796c81709d6152f127057425/fx42.sml</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2862</xocs:filesize>
               <xocs:pixel-height>59</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx22/THUMBNAIL/image/gif/fefb1c3929be0af4b06389246e48026a/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2962</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx60.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx60/THUMBNAIL/image/gif/cdc479f2a00079a730a606344eb568bb/fx60.sml</xocs:ucs-locator>
               <xocs:file-basename>fx60</xocs:file-basename>
               <xocs:filename>fx60.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2824</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc3/THUMBNAIL/image/gif/d82107388ae90d675d7d92d490ed100d/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3257</xocs:filesize>
               <xocs:pixel-height>67</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr5/THUMBNAIL/image/gif/df76495a14f4155a6844101cac8e76ba/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13513</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>217</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx7/THUMBNAIL/image/gif/30f489853ea7f8316c5d2ae7fe19618e/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3820</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx44.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx44/THUMBNAIL/image/gif/b3f9c16e3fc4e6d83c336617470de844/fx44.sml</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2865</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx55.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx55/THUMBNAIL/image/gif/8235cab833f6fff1e422818fbf36ed7d/fx55.sml</xocs:ucs-locator>
               <xocs:file-basename>fx55</xocs:file-basename>
               <xocs:filename>fx55.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1649</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx63.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx63/THUMBNAIL/image/gif/de41e27e662c983343f20f4d5dbc4534/fx63.sml</xocs:ucs-locator>
               <xocs:file-basename>fx63</xocs:file-basename>
               <xocs:filename>fx63.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1678</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx33.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx33/THUMBNAIL/image/gif/56ac2796220ac3f28b16b449c822582b/fx33.sml</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1675</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx50_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx50/HIGHRES/image/jpeg/8ec2ea24efbbe37b260170641cc86347/fx50_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx50</xocs:file-basename>
               <xocs:filename>fx50_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4023</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx19/HIGHRES/image/jpeg/d2308082d2d340c4f59db16d5df5fd6a/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3217</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx69_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx69/HIGHRES/image/jpeg/ac07e48c0b66618cee3a9a6b080645a8/fx69_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx69</xocs:file-basename>
               <xocs:filename>fx69_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3271</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc1/HIGHRES/image/jpeg/644121cb15b334432846631029c0f5b0/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>122950</xocs:filesize>
               <xocs:pixel-height>1013</xocs:pixel-height>
               <xocs:pixel-width>1691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr6/HIGHRES/image/jpeg/f2591ef05e33823ff06a0dd6b0e5159b/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>223989</xocs:filesize>
               <xocs:pixel-height>1026</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx5/HIGHRES/image/jpeg/68d92ea286534dbc63ef578623861186/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4022</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>256</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx23/HIGHRES/image/jpeg/e439b18d06841ac68452d2d3b3e1fe13/fx23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3219</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx66_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx66/HIGHRES/image/jpeg/f100a3b6ea1ab8625b33b3182b1f5821/fx66_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx66</xocs:file-basename>
               <xocs:filename>fx66_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4354</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx40_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx40/HIGHRES/image/jpeg/1e3bd84205450d7d7b5e46efe0573cd4/fx40_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4502</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx56_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx56/HIGHRES/image/jpeg/fae7853553f65ce4243c7931d7c86f8c/fx56_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx56</xocs:file-basename>
               <xocs:filename>fx56_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4500</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx48_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx48/HIGHRES/image/jpeg/7192eb10f0aee17adf995a926d9e529d/fx48_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx48</xocs:file-basename>
               <xocs:filename>fx48_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5359</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx59_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx59/HIGHRES/image/jpeg/e332ac806a671571ccb7c7dccbcadce1/fx59_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx59</xocs:file-basename>
               <xocs:filename>fx59_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2818</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx2/HIGHRES/image/jpeg/cb5df0e669dbb9b9dae3423bc892d09e/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>73193</xocs:filesize>
               <xocs:pixel-height>575</xocs:pixel-height>
               <xocs:pixel-width>1464</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx51_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx51/HIGHRES/image/jpeg/4f603ac2b092914aef5f6db323c4eafb/fx51_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx51</xocs:file-basename>
               <xocs:filename>fx51_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2816</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx62_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx62/HIGHRES/image/jpeg/f35bc190c5f6c52afebe9e22b649469a/fx62_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx62</xocs:file-basename>
               <xocs:filename>fx62_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4497</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx36_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx36/HIGHRES/image/jpeg/556d2acca4cd8471774973bea13d9d8d/fx36_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3088</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx54_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx54/HIGHRES/image/jpeg/761ce4c99265394b5d019ecf72ae961b/fx54_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx54</xocs:file-basename>
               <xocs:filename>fx54_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4502</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx57_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx57/HIGHRES/image/jpeg/166662012772fd4bfa4766f7063b3a51/fx57_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx57</xocs:file-basename>
               <xocs:filename>fx57_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3270</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx9/HIGHRES/image/jpeg/f781881a48f12dfda7aa861b61ea2035/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4490</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>259</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx35_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx35/HIGHRES/image/jpeg/230317e8bfc7a6d985da8e28cce6d2b3/fx35_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3269</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx67_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx67/HIGHRES/image/jpeg/5c38a0d8a9a90e754587beec96dd26e0/fx67_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx67</xocs:file-basename>
               <xocs:filename>fx67_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2814</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr2/HIGHRES/image/jpeg/2c5e5f9c56bbe2181e40aa8835109203/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>506551</xocs:filesize>
               <xocs:pixel-height>2107</xocs:pixel-height>
               <xocs:pixel-width>2657</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx39_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx39/HIGHRES/image/jpeg/b5d147e3eb876f6437237d2f00dc156e/fx39_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4856</xocs:filesize>
               <xocs:pixel-height>140</xocs:pixel-height>
               <xocs:pixel-width>236</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx58_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx58/HIGHRES/image/jpeg/14671d2ca09057bf6b39bab42e8e72e3/fx58_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx58</xocs:file-basename>
               <xocs:filename>fx58_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4364</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx3/HIGHRES/image/jpeg/eac782ea0442abbbc95c0b38567889ae/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3119</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>164</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr1/HIGHRES/image/jpeg/8e09d6cdbcecc05c7bde8f6a28ff0efe/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>278773</xocs:filesize>
               <xocs:pixel-height>1566</xocs:pixel-height>
               <xocs:pixel-width>2318</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx61_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx61/HIGHRES/image/jpeg/e66bf42299cd69d89a6523fa3a1832d8/fx61_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx61</xocs:file-basename>
               <xocs:filename>fx61_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3272</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx20/HIGHRES/image/jpeg/186cdf595f175e3398b19043a9fdb5b6/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4498</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx26_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx26/HIGHRES/image/jpeg/9da8ebaa4c41d8d30d4cf32c1ee301d1/fx26_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4367</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx34_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx34/HIGHRES/image/jpeg/be3d168e3f392e9903b96d5fc2485564/fx34_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4553</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx41_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx41/HIGHRES/image/jpeg/43b44a7aa80b1cbb17f735433bfe8c7e/fx41_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4576</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>263</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx46_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx46/HIGHRES/image/jpeg/9bbbbd50e7e785b063c36be53f3e560d/fx46_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx46</xocs:file-basename>
               <xocs:filename>fx46_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4360</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc2/HIGHRES/image/jpeg/04d12812124a97da0b4f9deb7b7ec3e1/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>276759</xocs:filesize>
               <xocs:pixel-height>1888</xocs:pixel-height>
               <xocs:pixel-width>2461</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx29_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx29/HIGHRES/image/jpeg/22b0ae2db5b05573cb3cb31018d7f09d/fx29_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2807</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx8/HIGHRES/image/jpeg/835c54678e685a17d604de952ae6fb58/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4334</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>239</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx14/HIGHRES/image/jpeg/1500313d1eb39818d5500dc6e652875f/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4031</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>256</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx1/HIGHRES/image/jpeg/3c8ff7c99a5473a5c7ca2f723b75ca56/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>251353</xocs:filesize>
               <xocs:pixel-height>782</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr7/HIGHRES/image/jpeg/54e24ff16e391e59fed9770c6e5da791/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>453654</xocs:filesize>
               <xocs:pixel-height>1771</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr3/HIGHRES/image/jpeg/2be920248e46191748a036706fdef9dc/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>649596</xocs:filesize>
               <xocs:pixel-height>1743</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx25/HIGHRES/image/jpeg/f2db2c2184284d6de508596da7bbf30d/fx25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2831</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx18/HIGHRES/image/jpeg/4c70e65e431471fd5d031009c36ea561/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3102</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx4/HIGHRES/image/jpeg/83f9598f7c2e5501c1e8a85babbd895e/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4486</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>259</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx13/HIGHRES/image/jpeg/501a165f0614b661db894f23dd519e75/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4494</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>259</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx32_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx32/HIGHRES/image/jpeg/3e043181790d2af309e11044564edb46/fx32_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4251</xocs:filesize>
               <xocs:pixel-height>82</xocs:pixel-height>
               <xocs:pixel-width>234</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx15/HIGHRES/image/jpeg/24d51d7cc30eb096d9cf9250ad4fa5b8/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72218</xocs:filesize>
               <xocs:pixel-height>558</xocs:pixel-height>
               <xocs:pixel-width>1459</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx47_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx47/HIGHRES/image/jpeg/e46a5e73bb54de26a9d3cfdae2a8a4ff/fx47_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx47</xocs:file-basename>
               <xocs:filename>fx47_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4981</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>282</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr4/HIGHRES/image/jpeg/6ded0f3402f884948a9456c966d35058/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>256677</xocs:filesize>
               <xocs:pixel-height>910</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx24/HIGHRES/image/jpeg/bb52482112c7a1d7d75bfe7395ddd521/fx24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4363</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx17/HIGHRES/image/jpeg/f607fbc9f7e4fdb22da2c8e4223ac763/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2838</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx37_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx37/HIGHRES/image/jpeg/0a9721cd75814b759db11ff0c7fce063/fx37_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4980</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>282</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx43_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx43/HIGHRES/image/jpeg/e2e4b5eb472a46e40f345fd0381a575f/fx43_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4858</xocs:filesize>
               <xocs:pixel-height>140</xocs:pixel-height>
               <xocs:pixel-width>236</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx38_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx38/HIGHRES/image/jpeg/b78e49082f2443d09eab6b8858c90edc/fx38_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4509</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx31_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx31/HIGHRES/image/jpeg/4826e3e81c1c3e1650f0756477131600/fx31_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2812</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx64_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx64/HIGHRES/image/jpeg/7f9c2631fffc803fedcd21fe4bb18908/fx64_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx64</xocs:file-basename>
               <xocs:filename>fx64_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4500</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx49_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx49/HIGHRES/image/jpeg/d183a89a960a3ade917fc7dc8235c7f5/fx49_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx49</xocs:file-basename>
               <xocs:filename>fx49_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4986</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>282</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx65_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx65/HIGHRES/image/jpeg/f4b72fc4fc742e3453254bb56766d734/fx65_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx65</xocs:file-basename>
               <xocs:filename>fx65_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3280</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr8/HIGHRES/image/jpeg/541d2414eecc24e9f8909b019c12434d/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1125108</xocs:filesize>
               <xocs:pixel-height>2449</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx53_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx53/HIGHRES/image/jpeg/5a7c967aed9a75e15e7d3e812ba20e3d/fx53_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx53</xocs:file-basename>
               <xocs:filename>fx53_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3277</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx52_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx52/HIGHRES/image/jpeg/8a03968793a1e997b258306d1bee7407/fx52_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx52</xocs:file-basename>
               <xocs:filename>fx52_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4367</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx68_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx68/HIGHRES/image/jpeg/47d9ca6fba15684d830939921d427600/fx68_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx68</xocs:file-basename>
               <xocs:filename>fx68_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4365</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx45_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx45/HIGHRES/image/jpeg/20cb685054cb8ec78a5aa3b1f6bc86ad/fx45_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4579</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>263</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx16/HIGHRES/image/jpeg/1a7f6aa1a46b7b5fb3772ed27c72442c/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3105</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx30_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx30/HIGHRES/image/jpeg/ce0cd2077d16874eadab3dc133fbb7a9/fx30_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5452</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>242</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx27_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx27/HIGHRES/image/jpeg/f6ffcb0c41d81620ce90363f3ee42d76/fx27_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3272</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx21/HIGHRES/image/jpeg/be7e9405826d55bb1be6ed38a792ec6c/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2844</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx12/HIGHRES/image/jpeg/1ffcd247c4de5b5a1207a9c24863e831/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4024</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>256</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx10/HIGHRES/image/jpeg/6562757039493c78f131e373b3698f46/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4027</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>256</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx28_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx28/HIGHRES/image/jpeg/3e903b787b2fc919b1e295a44fa8b568/fx28_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4634</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>241</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx6/HIGHRES/image/jpeg/3ad198d01e088e3971e4d95767f8766d/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4851</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>243</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx11/HIGHRES/image/jpeg/da1ef6881f023b40651338a77bb5de1c/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4505</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>259</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx42_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx42/HIGHRES/image/jpeg/443b1d615e6a608fbcdfa3bbf24daba3/fx42_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4351</xocs:filesize>
               <xocs:pixel-height>68</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx22/HIGHRES/image/jpeg/02a08279ebf5de94f56a02c444e8a55a/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4499</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>254</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx60_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx60/HIGHRES/image/jpeg/f43ef78fb4105a0109362309e1694617/fx60_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx60</xocs:file-basename>
               <xocs:filename>fx60_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4360</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/sc3/HIGHRES/image/jpeg/c53bda807f376f8c0a9df0a27f6104a9/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>128812</xocs:filesize>
               <xocs:pixel-height>710</xocs:pixel-height>
               <xocs:pixel-width>2338</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/gr5/HIGHRES/image/jpeg/b4dd8f7809583912b2a6dbc84064b26a/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>483514</xocs:filesize>
               <xocs:pixel-height>1939</xocs:pixel-height>
               <xocs:pixel-width>2571</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx7/HIGHRES/image/jpeg/8935ca84baee7988ae822aee989dbf35/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5490</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>243</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx44_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx44/HIGHRES/image/jpeg/f766cb54afda8a92f3e5f38582489d9d/fx44_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4361</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx55_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx55/HIGHRES/image/jpeg/06e85d94c48bcf2c719c5bf2c5f81d4a/fx55_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx55</xocs:file-basename>
               <xocs:filename>fx55_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2830</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx63_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx63/HIGHRES/image/jpeg/c06a9ce84e3240919ce705dab2053407/fx63_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx63</xocs:file-basename>
               <xocs:filename>fx63_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2841</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-fx33_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/fx33/HIGHRES/image/jpeg/8c8f2aa0d03eaf61ce6d342edc4a4dc6/fx33_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2815</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-mmc1.doc</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342030115X/mmc1/MAIN/application/msword/b80666f92aadf6247adcec10564cd778/mmc1.doc</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.doc</xocs:filename>
               <xocs:extension>doc</xocs:extension>
               <xocs:filesize>9677312</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342030115X-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1340540</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10JRP10MXT2/MAIN/application/pdf/da161a343f2ca982f41aecc2943b1b04/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112148</aid>
            <ce:article-number>112148</ce:article-number>
            <ce:pii>S0223-5234(20)30115-X</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112148</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Chemical structures of JAK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S022352342030115X/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Design of selective JAK3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S022352342030115X/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Compound <ce:bold>12</ce:bold> bound to JAK3 enzyme (PDB code: <ce:inter-ref id="intref0025" xlink:href="pdb:4Z16" xlink:type="simple">4Z16</ce:inter-ref>). 3D interaction diagram representing the docked conformation of compound <ce:bold>12</ce:bold> covalently binds to Cys909 of JAK3 enzyme.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S022352342030115X/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">The cell viability of <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> was determined by the MTS method. Resting mouse T cell (A), IL-4-treated activated T cell (B), and RAW264.7 cells (C) were respectively treated with compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> at 10 μM for 72 h, and cytotoxicity was expressed by the percentage of surviving cells over control cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S022352342030115X/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Compounds potently and selectively inhibited JAK3-dependent signaling in mouse T cells. After pre-incubating with compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> for 2 h at 10 μM, T cells were stimulated with IL-2 (A) or IL-15 (B) for another 30 min. The levels of p-STAT5 were determined by Western blot analysis. The concentration-dependent expression of p-STAT5 was further determined by indicated concentrations of compounds <ce:bold>11</ce:bold> and <ce:bold>12</ce:bold> for 2 h prior to IL-2 (C) or IL-15(D) stimulation to T cells. Tof (tofacitinib) served as a positive agent in this assay.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S022352342030115X/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">(A) Time-dependent inhibition curves of compound <ce:bold>12</ce:bold> and Tofacitinib. (B) JAK3 enzymatic activity was not restored up to 24 h after diluting from an IC<ce:inf loc="post">90</ce:inf> to an IC<ce:inf loc="post">10</ce:inf> concentration of compound <ce:bold>12</ce:bold> (blue) when compared to a DMSO control (red). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S022352342030115X/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">The effect of compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> on oxazolone (OXZ)-induced delayed type hypersensitivity (DTH) mouse model. (A) Timeline for the process of DTH development and treatment. Ear weight (B), the percentage of ear swelling (C), and the spleen index (D) were presented to evaluate the effect of compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> on OXZ-induced DTH responses. Tofacitinib served as a positive agent for compounds. Data are presented as the mean ± SEM. n = 5–6 per group for treated mice and 3 for control mice. <ce:sup loc="post">###</ce:sup>
                     <ce:italic>p</ce:italic> < 0.001 versus control group; *<ce:italic>p</ce:italic> < 0.05, **<ce:italic>p</ce:italic> < 0.01, and ***<ce:italic>p</ce:italic> < 0.001 versus vehicle group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S022352342030115X/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Immunosuppressive effects of compound <ce:bold>12</ce:bold> on oxazolone-induced delayed type hypersensitivity mice. (A–C) Compound <ce:bold>12</ce:bold> (30, 10, and 3 mg/kg, p.o.) inhibited oxazolone (OXZ)-induced delayed type hypersensitivity (DTH) responses in a dose-dependent manner. (D) The effect of compound <ce:bold>12</ce:bold> on histopathological changes and inflammatory cell infiltration were evaluated by HE-staining in ear tissue. Scale bar 200 μm. Tofacitinib was positive agent and compared with compound <ce:bold>12</ce:bold>. Data are the mean ± SEM. n = 5–6 per group for treated mice and 3 for control mice. <ce:sup loc="post">###</ce:sup>
                     <ce:italic>p</ce:italic> < 0.001 versus control group; *<ce:italic>p</ce:italic> < 0.05, **<ce:italic>p</ce:italic> < 0.01, and ***<ce:italic>p</ce:italic> < 0.001 versus vehicle group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S022352342030115X/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Reagents and conditions: (i) bis(pinacolato)diboron, 1,4-dioxane/H<ce:inf loc="post">2</ce:inf>O, Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf>, KOAc, 100 °C, 12 h; (ii) 1,4-dioxane/H<ce:inf loc="post">2</ce:inf>O, Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, 100 °C, 12 h; (iii) amine, DIEA, isopropanol, 82 °C, 6h; (iv) Pd/C, hydrazine hydrate, EtOH, 100 °C, 2h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S022352342030115X/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Reagents and conditions: (i) acyl chlorides, THF, 0 °C to room temperature (RT), 30min; (ii) cyanoacetic acid, HATU, DIEA, THF, 16h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S022352342030115X/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Reagents and conditions: (i) Boc-glycine, EDCI, HOBT, DIEA, DCM, 8h; (ii) TFA, DCM, 5h; (iii) acyl chlorides, THF, 0 °C to room temperature (RT), 30min; (iv) cyanoacetic acid, HATU, DIEA, THF, 16h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S022352342030115X/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0010" view="all">The selectivity of JAK inhibitors in a cell-free enzyme assay.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Table 1</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col4" namest="col2" role="colgroup">IC<inf loc="post">50</inf>
                           <cross-ref id="crosref0385" refid="tbl1fna">
                              <sup loc="post">a</sup>
                           </cross-ref>(nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">JAK3/JAK2<cross-ref id="crosref0390" refid="tbl1fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">JAK3/JAK1<cross-ref id="crosref0395" refid="tbl1fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ruxolitinib [<cross-ref id="crosref0400" refid="bib6">6</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>400</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>133</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>133</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Baricitinib [<cross-ref id="crosref0405" refid="bib7">7</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>400</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>67</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Upadacitinib [<cross-ref id="crosref0410" refid="bib8">8</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2304</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">120</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">49</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Peficitinib [<cross-ref id="crosref0415" refid="bib9">9</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tofacitinib<cross-ref id="crosref0420" refid="tbl1fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">112</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-06651600 [<cross-ref id="crosref0425" refid="bib15">15</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">IC<ce:inf loc="post">50</ce:inf> against JAK3, JAK2, JAK1 in enzyme assay.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Fold selectivity derived from JAK3/JAK2 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0025" view="all">Fold selectivity derived from JAK3/JAK1 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0030" view="all">Tofacitinib is originally described as being selective for JAK3 [<ce:cross-ref id="crosref0430" refid="bib10">10</ce:cross-ref>], however it was later proven to be a pan-JAK inhibitor [<ce:cross-ref id="crosref0435" refid="bib11">11</ce:cross-ref>].</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0015" view="all">SARs of side chains (R<ce:inf loc="post">1</ce:inf>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Table 2</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S022352342030115X/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col3" role="colgroup">IC<inf loc="post">50</inf>
                           <cross-ref id="crosref0440" refid="tbl2fna">
                              <sup loc="post">a</sup>
                           </cross-ref> (nM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2 JAK2/JAK3<cross-ref id="crosref0445" refid="tbl2fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK1 JAK1/JAK3<cross-ref id="crosref0450" refid="tbl2fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TYK2 TYK2/JAK3<cross-ref id="crosref0455" refid="tbl2fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S022352342030115X/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">303</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2237<br/></br>[7]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">657<br/></br>[2]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0460" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S022352342030115X/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">101</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2852<br/></br>[28]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">568<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0465" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S022352342030115X/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">183</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2043<br/></br>[11]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1107<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0470" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S022352342030115X/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">309</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">731<br/></br>[<cross-ref id="crosref0475" refid="bib2">2</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0480" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S022352342030115X/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">138</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0485" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">840<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0490" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S022352342030115X/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">599</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2588<br/></br>[4]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0495" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0500" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S022352342030115X/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0115" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>55</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1286<br/></br>[23]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1102<br/></br>[20]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2871<br/></br>[52]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S022352342030115X/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0120" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1796<br/></br>[60]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2119<br/></br>[71]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2439<br/></br>[30]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S022352342030115X/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0125" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1658<br/></br>[25]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S022352342030115X/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">112</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1569<br/></br>[14]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">961<br/></br>[9]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0505" refid="tbl2fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S022352342030115X/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>9.1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1079<br/></br>[119]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1562<br/></br>[172]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:href="pii:S022352342030115X/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0140" role="short">Image 14</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1.7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1000<br/></br>
                           <bold>[588]</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1320<br/></br>
                           <bold>[777]</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2783<br/></br>[1637]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Tofacitinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.5<br/></br>[1.7]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3<br/></br>[1.1]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.5<br/></br>[39.4]</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0035" view="all">IC<ce:inf loc="post">50</ce:inf> values are the average of duplicate experiments.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0040" view="all">Fold selectivity derived from JAK2/JAK3 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0045" view="all">Fold selectivity derived from JAK1/JAK3 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0050" view="all">Fold selectivity derived from TYK2/JAK3 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fne">
                  <ce:label>e</ce:label>
                  <ce:note-para id="ntpara0055" view="all">ND = not determined.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0020" view="all">SARs of side chains (R<ce:inf loc="post">2</ce:inf>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0145" role="short">Table 3</ce:alt-text>
               <ce:link locator="fx15" xlink:href="pii:S022352342030115X/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="7">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col7" namest="col4" role="colgroup">IC<inf loc="post">50</inf>
                           <cross-ref id="crosref0510" refid="tbl3fna">
                              <sup loc="post">a</sup>
                           </cross-ref> (nM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2 JAK2/JAK3<cross-ref id="crosref0515" refid="tbl3fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK1 JAK1/JAK3<cross-ref id="crosref0520" refid="tbl3fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TYK2 TYK2/JAK3<cross-ref id="crosref0525" refid="tbl3fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S022352342030115X/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S022352342030115X/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0155" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">567</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2761<br/></br>[5]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1521<br/></br>[3]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0530" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:href="pii:S022352342030115X/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0160" role="short">Image 18</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx19" xlink:href="pii:S022352342030115X/fx19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0165" role="short">Image 19</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">145</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0535" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">854<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0540" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:href="pii:S022352342030115X/fx20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0170" role="short">Image 20</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:href="pii:S022352342030115X/fx21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0175" role="short">Image 21</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2580<br/></br>[89]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1286<br/></br>[44]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:href="pii:S022352342030115X/fx22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0180" role="short">Image 22</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx23" xlink:href="pii:S022352342030115X/fx23" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0185" role="short">Image 23</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">587<br/></br>[9]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">322<br/></br>[5]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2264<br/></br>[35]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx24" xlink:href="pii:S022352342030115X/fx24" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0190" role="short">Image 24</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx25" xlink:href="pii:S022352342030115X/fx25" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0195" role="short">Image 25</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2129<br/></br>[61]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2876<br/></br>[82]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx26" xlink:href="pii:S022352342030115X/fx26" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0200" role="short">Image 26</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx27" xlink:href="pii:S022352342030115X/fx27" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0205" role="short">Image 27</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">170</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">734<br/></br>[4]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1861<br/></br>[11]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0545" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx28" xlink:href="pii:S022352342030115X/fx28" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0210" role="short">Image 28</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx29" xlink:href="pii:S022352342030115X/fx29" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0215" role="short">Image 29</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1886<br/></br>[28]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">899<br/></br>[13]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0550" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx30" xlink:href="pii:S022352342030115X/fx30" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0220" role="short">Image 30</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx31" xlink:href="pii:S022352342030115X/fx31" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0225" role="short">Image 31</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1109<br/></br>[12]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0555" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0560" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx32" xlink:href="pii:S022352342030115X/fx32" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0230" role="short">Image 32</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx33" xlink:href="pii:S022352342030115X/fx33" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0235" role="short">Image 33</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">221</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2808<br/></br>[13]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2443<br/></br>[11]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0565" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx34" xlink:href="pii:S022352342030115X/fx34" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0240" role="short">Image 34</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx35" xlink:href="pii:S022352342030115X/fx35" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0245" role="short">Image 35</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">243</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1143<br/></br>[5]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1542<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0570" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx36" xlink:href="pii:S022352342030115X/fx36" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0250" role="short">Image 36</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx37" xlink:href="pii:S022352342030115X/fx37" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0255" role="short">Image 37</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">95</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">69<br/></br>[1]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">89<br/></br>[1]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0575" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx38" xlink:href="pii:S022352342030115X/fx38" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0260" role="short">Image 38</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx39" xlink:href="pii:S022352342030115X/fx39" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0265" role="short">Image 39</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1542<br/></br>[23]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">56<br/></br>[1]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0580" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx40" xlink:href="pii:S022352342030115X/fx40" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0270" role="short">Image 40</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx41" xlink:href="pii:S022352342030115X/fx41" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0275" role="short">Image 41</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">108</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">886<br/></br>[<cross-ref id="crosref0585" refid="bib9">9</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45<br/></br>[0.4]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0590" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx42" xlink:href="pii:S022352342030115X/fx42" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0280" role="short">Image 42</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx43" xlink:href="pii:S022352342030115X/fx43" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0285" role="short">Image 43</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">103</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">354<br/></br>[3]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0595" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx44" xlink:href="pii:S022352342030115X/fx44" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0290" role="short">Image 44</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx45" xlink:href="pii:S022352342030115X/fx45" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0295" role="short">Image 45</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">375</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0600" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">586<br/></br>[2]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0605" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx46" xlink:href="pii:S022352342030115X/fx46" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0300" role="short">Image 46</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx47" xlink:href="pii:S022352342030115X/fx47" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0305" role="short">Image 47</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">253</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">309<br/></br>[1]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1432<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0610" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx48" xlink:href="pii:S022352342030115X/fx48" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0310" role="short">Image 48</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx49" xlink:href="pii:S022352342030115X/fx49" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0315" role="short">Image 49</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">127</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2732<br/></br>[22]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0615" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx50" xlink:href="pii:S022352342030115X/fx50" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0320" role="short">Image 50</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx51" xlink:href="pii:S022352342030115X/fx51" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0325" role="short">Image 51</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2788<br/></br>[85]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0620" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2653<br/></br>[577]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>31</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx52" xlink:href="pii:S022352342030115X/fx52" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0330" role="short">Image 52</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx53" xlink:href="pii:S022352342030115X/fx53" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0335" role="short">Image 53</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">152</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">216<br/></br>[1]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2233<br/></br>[15]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx54" xlink:href="pii:S022352342030115X/fx54" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0340" role="short">Image 54</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx55" xlink:href="pii:S022352342030115X/fx55" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0345" role="short">Image 55</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0625" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2764<br/></br>[36]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0630" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>33</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx56" xlink:href="pii:S022352342030115X/fx56" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0350" role="short">Image 56</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx57" xlink:href="pii:S022352342030115X/fx57" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0355" role="short">Image 57</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1459<br/></br>[17]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2677<br/></br>[31]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1872<br/></br>[22]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>34</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx58" xlink:href="pii:S022352342030115X/fx58" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0360" role="short">Image 58</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx59" xlink:href="pii:S022352342030115X/fx59" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0365" role="short">Image 59</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">99</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2155<br/></br>[22]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">321<br/></br>[3]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0635" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>35</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx60" xlink:href="pii:S022352342030115X/fx60" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0370" role="short">Image 60</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx61" xlink:href="pii:S022352342030115X/fx61" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0375" role="short">Image 61</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0640" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">528<br/></br>[7]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0645" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>36</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx62" xlink:href="pii:S022352342030115X/fx62" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0380" role="short">Image 62</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx63" xlink:href="pii:S022352342030115X/fx63" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0385" role="short">Image 63</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1981<br/></br>[142]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1445<br/></br>[103]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>37</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx64" xlink:href="pii:S022352342030115X/fx64" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0390" role="short">Image 64</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx65" xlink:href="pii:S022352342030115X/fx65" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0395" role="short">Image 65</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0650" refid="tbl3fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                           <br/></br>
                           <sup loc="post">-</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">183<br/></br>[8]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2496<br/></br>[104]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx66" xlink:href="pii:S022352342030115X/fx66" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0400" role="short">Image 66</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx67" xlink:href="pii:S022352342030115X/fx67" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0405" role="short">Image 67</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>6.1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1412<br/></br>
                           <bold>[232]</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1147<br/></br>
                           <bold>[188]</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx68" xlink:href="pii:S022352342030115X/fx68" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0410" role="short">Image 68</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx69" xlink:href="pii:S022352342030115X/fx69" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0415" role="short">Image 69</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">88<br/></br>[6]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">433<br/></br>[29]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>3000<br/></br>–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Tofacitinb</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.5<br/></br>[1.7]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3<br/></br>[1.4]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.5<br/></br>[39.4]</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl3fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0060" view="all">IC<ce:inf loc="post">50</ce:inf> values are the average of duplicate experiments.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl3fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0065" view="all">Fold selectivity derived from JAK2/JAK3 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl3fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0070" view="all">Fold selectivity derived from JAK1/JAK3 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl3fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0075" view="all">Fold selectivity derived from TYK2/JAK3 enzyme IC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl3fne">
                  <ce:label>e</ce:label>
                  <ce:note-para id="ntpara0080" view="all">ND = not determined.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0025" view="all">The effects of compounds inhibiting T cell proliferation after stimulation by anti-CD3/-CD28 or IL-2.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0420" role="short">Table 4</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col3" namest="col2" role="colgroup">Inhibition of T cell proliferation, IC<inf loc="post">50</inf>(μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">
                           <italic>C</italic>log<italic>P</italic>
                           <cross-ref id="crosref0655" refid="tbl4fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">anti-CD3/-CD28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-2</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.49</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>0.83</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>0.77</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.77</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1.60</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2.11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Tofacitinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.38</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.54</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0085" view="all">Calculated as miLogP using Molinspiration property engine version 2018.10 (<ce:inter-ref id="intref0030" xlink:href="http://www.molinspiration.com" xlink:type="simple">http://www.molinspiration.com</ce:inter-ref>).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl5" rowsep="0">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0030" view="all">The inhibitory activity of compound <ce:bold>12</ce:bold> (100 nM) on other kinases.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0425" role="short">Table 5</ce:alt-text>
               <tgroup cols="11">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <colspec colname="col11" colnum="11"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col11" namest="col2" role="colgroup">Inhibition rate (%)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">BLK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">BMK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">BTK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">EGFR (ErbB1)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ERBB2 (HER2)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ERBB4 (HER4)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ITK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">RLK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TEC</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.5</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0035" view="all">Biochemical assays were conducted using SelectScreen® Kinase Profiling by Z′-LYTE (TEC by Lantha Screen) at the Km concentration of ATP.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl6" rowsep="0">
               <ce:label>Table 6</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="tspara0040" view="all">Preliminary pharmacokinetic data of compound <ce:bold>12</ce:bold> in male ICR Mice.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0430" role="short">Table 6</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound 12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">iv (10 mg/kg)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">po (30 mg/kg)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AUC(0-t) (μg/L*h)<cross-ref id="crosref0660" refid="tbl6fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1244.41 ± 77.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">889.42 ± 48.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AUC(0-∞) (μg/L*h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1274.41 ± 57.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">897.12 ± 56.72</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MRT (0-∞) (h)<cross-ref id="crosref0665" refid="tbl6fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.73 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.42 ± 0.38</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Vz (L/kg)<cross-ref id="crosref0670" refid="tbl6fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.36 ± 1.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">220.42 ± 24.71</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CLz (L/h/kg)<cross-ref id="crosref0675" refid="tbl6fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.15 ± 1.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">97.14 ± 20.87</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">1/2</inf> (h)<cross-ref id="crosref0680" refid="tbl6fne">
                              <sup loc="post">e</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.47 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.52 ± 0.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C<inf loc="post">max</inf> (μg/L)<cross-ref id="crosref0685" refid="tbl6fnf">
                              <sup loc="post">f</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8763.23 ± 324.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2008.21 ± 189.44</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bioavailability(%)<cross-ref id="crosref0690" refid="tbl6fng">
                              <sup loc="post">g</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.82%</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl6fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0090" view="all">Area under the concentration time curve.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl6fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0095" view="all">Mean residence time.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl6fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0100" view="all">Volume in steady state.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl6fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0105" view="all">Plasma clearance.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl6fne">
                  <ce:label>e</ce:label>
                  <ce:note-para id="ntpara0110" view="all">Terminal half-life.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl6fnf">
                  <ce:label>f</ce:label>
                  <ce:note-para id="ntpara0115" view="all">Peak plasma concentrations.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl6fng">
                  <ce:label>g</ce:label>
                  <ce:note-para id="ntpara0120" view="all">Bioavailability = AUC<ce:inf loc="post">0–t</ce:inf>(po)/AUC<ce:inf loc="post">0–t</ce:inf>(iv) × 100%.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S022352342030115X-5c981f93b011171bede483e436acdb95">
                  <ce:given-name>Lei</ce:given-name>
                  <ce:surname>Shu</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S022352342030115X-f5478533c1694a41fbc15c33ae25b422">
                  <ce:given-name>Chengjuan</ce:given-name>
                  <ce:surname>Chen</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S022352342030115X-d4ec1ee8101662fdc2487a4a28c308a7">
                  <ce:given-name>Xueting</ce:given-name>
                  <ce:surname>Huan</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S022352342030115X-2b9fb939c1250ff89fc39c28db6d535c">
                  <ce:given-name>Hao</ce:given-name>
                  <ce:surname>Huang</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S022352342030115X-7bc686bde47365b8f94da9a0e8029851">
                  <ce:given-name>Manman</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S022352342030115X-815f25b0b89be049782410344156ee45">
                  <ce:given-name>Jianqiu</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S022352342030115X-efcaa2716fa6aeb47bc871fea4d14679">
                  <ce:given-name>Yile</ce:given-name>
                  <ce:surname>Yan</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S022352342030115X-a3da61e4602f775f416633d67ef4048d">
                  <ce:given-name>Jianming</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S022352342030115X-14cd65548cbd5e894bac4f0a7970acaa">
                  <ce:given-name>Tiantai</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au10" author-id="S022352342030115X-e141f6ba030a8c815842aa0ccc03d236">
                  <ce:given-name>Dayong</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S022352342030115X-5021e50d35d0c3a98167e4d511b7460a">
                  <ce:label>a</ce:label>
                  <ce:textfn>Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, 210009, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institute of Pharmaceutical Science</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, 210009, PR China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S022352342030115X-80bb48ef01309af5a024cf035c0533d1">
                  <ce:label>b</ce:label>
                  <ce:textfn>State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100050, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>State Key Laboratory of Bioactive Substance and Function of Natural Medicines</sa:organization>
                     <sa:organization>Institute of Materia Medica</sa:organization>
                     <sa:organization>Chinese Academy of Medical Sciences</sa:organization>
                     <sa:organization>Peking Union Medical College</sa:organization>
                     <sa:city>Beijing</sa:city>
                     <sa:postal-code>100050</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, PR China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="30" month="11" year="2019"/></ce:date-received>
            <ce:date-revised day="13" month="2" year="2020"/></ce:date-revised>
            <ce:date-accepted day="13" month="2" year="2020"/></ce:date-accepted>
            <ce:abstract class="author" id="abs0010" xml:lang="en" view="all"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">As non-receptor tyrosine kinases, Janus kinases (JAKs) have become an attractive target for the treatment of autoimmune diseases and cancers. JAKs play a pivotal role in innate immunity, inflammation, and hematopoiesis by mediating the signaling of numerous cytokines, growth factors, and interferons (IFNs). Selective inhibitors of a variety of JAK members are expected to inhibit pro-inflammatory cytokine-mediated inflammation and immune responses, while preventing targeting other subtypes of JAKs. In this work, poorly selective compounds based on 4- or 6-phenyl-pyrimidine derivatives have been improved to highly potent and selective compounds by designing a covalent binding tether, which attaches to the unique cysteine (Cys909) residue in JAK3. Compound <ce:bold>12</ce:bold> exhibited potent JAK3 inhibitory activity (IC<ce:inf loc="post">50</ce:inf> = 1.7 nM) with an excellent selectivity profile when compared to the other JAK isoforms (>588-fold). In a cellular assay, compound <ce:bold>12</ce:bold> strongly inhibited JAK3-dependent signaling and T cell proliferation. Moreover, <ce:italic>in vivo</ce:italic> data revealed that compound <ce:bold>12</ce:bold> significantly suppressed oxazolone (OXZ)-induced delayed hypersensitivity responses in Balb/c mice. Compound <ce:bold>12</ce:bold> also displayed decent pharmacokinetic properties and was suitable for <ce:italic>in vivo</ce:italic> use. Taken together, these results indicated that compound <ce:bold>12</ce:bold> may be a promising tool compound as a selective JAK3 inhibitor for treating autoimmune diseases.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S022352342030115X/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords class="keyword" id="kwrds0010" xml:lang="en" view="all">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Autoimmune diseases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Covalent JAK3 inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Cys909</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Janus kinase</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>4- or 6-phenyl-pyrimidine derivatives</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are a small family of non-receptor tyrosine kinases that are essential for mediating the signaling cascade that is associated with multiple cytokines by activating signal transducer and activator transcription (STAT) [<ce:cross-ref id="crosref0080" refid="bib1">1</ce:cross-ref>]. The JAK-STAT pathway is considered as an evolutionarily conserved signaling pathway involved in the regulation of immune and inflammatory disease [<ce:cross-ref id="crosref0085" refid="bib2">2</ce:cross-ref>]. Binding of cytokines with their distinct receptor is the trigger for activation of JAKs, and upon activation STATs bind to phosphorylated cytokine receptors and undergo phosphorylation by JAKs [<ce:cross-ref id="crosref0090" refid="bib3">3</ce:cross-ref>]. Subsequently, dimerized STATs translocate to the nucleus and drive gene transcription, thereby regulating the immune system and inflammatory responses [<ce:cross-ref id="crosref0095" refid="bib4">4</ce:cross-ref>]. With the first US Food and Drug Administration (FDA)-approved pan-JAKs small molecule inhibitor tofacitinib [<ce:cross-ref id="crosref0100" refid="bib5">5</ce:cross-ref>,<ce:cross-ref id="crosref0105" refid="bib10">10</ce:cross-ref>,<ce:cross-ref id="crosref0110" refid="bib11">11</ce:cross-ref>] for the treatment of rheumatoid arthritis (RA), the development of small molecule JAK inhibitors became attractive for treatment of autoimmune and inflammatory diseases.</ce:para>
                  <ce:para id="p0035" view="all">In recent years, significant research efforts have been performed towards the discovery of inhibitors of JAK kinases. As shown in <ce:cross-ref id="crosref0115" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor> and <ce:cross-ref id="crosref0120" refid="tbl1">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor>, several small-molecule inhibitors are current in the clinical or preclinical stage for the treatment of autoimmune diseases, various cancers, and myeloproliferative disorders [<ce:cross-refs id="crosrefs0010" refid="bib5 bib6 bib7 bib8 bib9 bib10 bib11 bib12 bib13 bib14 bib15 bib16">5–16</ce:cross-refs>]. For the first-generation of non-selective JAKs inhibitors that have been proven safe and efficacious, their broad inhibiting spectrums for cytokines inevitably lead to side effects by inhibiting many factors that can drive immunopathology. However, the next generation selective JAKs inhibitors are expected to be developed and prevent targeting other subtypes of JAKs. In August 2019, the selective JAK1 inhibitor upadacitinib [<ce:cross-refs id="crosrefs0015" refid="bib12 bib13 bib14">12–14</ce:cross-refs>], as a second-generation JAKs inhibitor, was first approved by the US FDA for the treatment of RA. PF-06651600 [<ce:cross-ref id="crosref0125" refid="bib15">15</ce:cross-ref>,<ce:cross-ref id="crosref0130" refid="bib16">16</ce:cross-ref>] has been reported as a selective JAK3 inhibitor that has been used in clinical trials.</ce:para>
                  <ce:para id="p0040" view="all">Among members of the JAKs family, JAK3 exhibited predominant expression in the hematopoietic system versus other JAKs, and were ubiquitously expressed in a variety of cell types [<ce:cross-ref id="crosref0135" refid="bib17">17</ce:cross-ref>]. Another feature of JAK3 is that it is required for cytokine signaling, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which act through relative receptors that possess the common gamma chain (γc) cytokines receptor subunit [<ce:cross-ref id="crosref0140" refid="bib18">18</ce:cross-ref>]. Cytokine signaling through the γc receptor is essential for normal activity and function of the immune system [<ce:cross-ref id="crosref0145" refid="bib19">19</ce:cross-ref>]. In humans, loss of function mutation leading to JAK3 deficiency in γc results in severe combined immunodeficiency (SCID) [<ce:cross-ref id="crosref0150" refid="bib20">20</ce:cross-ref>]. A selective JAK3 inhibitor should only block common γc cytokine signaling to resulting in much narrower spectrum of cytokine activity compared to first-generation non-selective inhibitors and concomitant prevention of some the side effects. Human JAK3 has a unique cysteine residue (Cys909), which is replaced with a serine residue at the equivalent position in the other three isoforms of JAK1, JAK2, and TYK2 [<ce:cross-ref id="crosref0155" refid="bib21">21</ce:cross-ref>]. In crystal structure, this feature gives the opportunity to design a selective inhibitor for JAK3. Based on the difference of Cys909, targeting the Cys909 ATP-competitive binding site in a covalent manner would be an optimized strategy [<ce:cross-ref id="crosref0160" refid="bib22">22</ce:cross-ref>]. Recently, several selective JAK3 inhibitors have been reported to bind the Cys909 site with a covalent bond formation, leading to irreversible inhibition and high selectivity, including PF-06651600, which was reported to irreversibly covalently bind Cys909 in JAK3 [<ce:cross-ref id="crosref0165" refid="bib16">16</ce:cross-ref>,<ce:cross-ref id="crosref0170" refid="bib23">23</ce:cross-ref>]. Based on the essential role in the immune system as well as the crystal structure feature, JAK3 has been considered as a potential target for the treatment of autoimmune and inflammatory diseases.</ce:para>
                  <ce:para id="p0045" view="all">In our previous study, we reported a series of compounds, including the bicyclic structure of pyrrolopyrimidine or pyrazolopyrimidine targeting JAKs, however, their inhibitory potency and selectivity need to be further improved [<ce:cross-refs id="crosrefs0020" refid="bib24 bib25 bib26 bib27">24–27</ce:cross-refs>]. Herein, we aimed to generate potent substituted pyrimidine-based inhibitors that exploit an acrylamide electrophile to form a covalent bond with Cys909 in JAK3. In this study, 4- Or 6-phenyl-pyrimidine derivatives as potent JAK3 inhibitors were designed and synthesized (<ce:cross-ref id="crosref0175" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>). Covalent JAK3 inhibitor <ce:bold>(1)</ce:bold> has excellent biological activities against JAK3, both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> [<ce:cross-ref id="crosref0180" refid="bib23">23</ce:cross-ref>]. Furthermore, guided by the structure of CYT-387 [<ce:cross-ref id="crosref0185" refid="bib28">28</ce:cross-ref>,<ce:cross-ref id="crosref0190" refid="bib29">29</ce:cross-ref>] and <ce:italic>N</ce:italic>-(3-(7<ce:italic>H</ce:italic>-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl) acrylamide <ce:bold>(3)</ce:bold> [<ce:cross-ref id="crosref0195" refid="bib15">15</ce:cross-ref>], new molecules (<ce:bold>1</ce:bold>-<ce:bold>39</ce:bold>) were designed by further optimization. Our studies showed that compound <ce:bold>12</ce:bold> had significant potent JAK3 inhibitory activity and selectivity. Therefore, in this study, we report the design, synthesis, and structure-activity relationship (SAR) of 4- or 6-phenyl-pyrimidine JAK inhibitors.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0050" view="all">A series of 4- or 6-phenyl-pyrimidine derivatives and intermediates were synthesized according to the pathways described in <ce:cross-refs id="crosrefs0025" refid="sch1 sch2 sch3">Schemes 1–4</ce:cross-refs> (see <ce:cross-ref id="crosref0200" refid="appsec1">Scheme 4</ce:cross-ref>, supplementary material).</ce:para>
                     <ce:para id="p0055" view="all">As presented in <ce:cross-ref id="crosref0205" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>, 3-bromo-nitrobenzene reacted with bis(pinacolato)diboron, then commercially available 4,6-dichloropyrimidine was treated with benzene pinacol borate to provide intermediate <ce:bold>40</ce:bold> at moderate yield (74%). Next, intermediate <ce:bold>40</ce:bold> was treated with several types of amines that were prepared as previously reported [<ce:cross-ref id="crosref0210" refid="bib24">24</ce:cross-ref>] for R<ce:inf loc="post">1</ce:inf> to produce 6-phenyl-pyrimidine amine <ce:bold>41a</ce:bold>-<ce:bold>f</ce:bold> under alkaline conditions. Treatment of compounds <ce:bold>41a</ce:bold>-<ce:bold>f</ce:bold> with 85% hydrazine hydrate under nitrogen and Pd/C catalysis provided compounds <ce:bold>42a</ce:bold>-<ce:bold>f</ce:bold>.</ce:para>
                     <ce:para id="p0060" view="all">Intermediates <ce:bold>43</ce:bold>, <ce:bold>46</ce:bold>, and <ce:bold>49</ce:bold> were prepared following a synthetic procedure of that was similar to that of compound <ce:bold>40</ce:bold> (see <ce:cross-ref id="crosref0215" refid="appsec1">Scheme 4</ce:cross-ref>, supplementary material).</ce:para>
                     <ce:para id="p0065" view="all">As shown in <ce:cross-ref id="crosref0220" refid="sch3">Scheme 3</ce:cross-ref>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>, intermediates <ce:bold>42a</ce:bold>-<ce:bold>e</ce:bold> were condensed with Boc-glycine to produce compounds <ce:bold>52a</ce:bold>-<ce:bold>e</ce:bold>. Subsequently, Boc deprotection using TFA in DCM cleanly generate compounds <ce:bold>53a</ce:bold>-<ce:bold>e</ce:bold> at near quantitative yield. The target compounds were prepared as presented in <ce:cross-refs id="crosrefs0030" refid="sch2 sch3">Schemes 2 and 3</ce:cross-refs>, which involved two types of reactions. First, intermediates were reacted with acyl chlorides to generate the desired compounds under basic conditions. Subsequently, intermediates were treated with cyanoacetic acid using standard HATU conditions to generate compounds at good yield as previously reported [<ce:cross-ref id="crosref0225" refid="bib24">24</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">In vitro enzymatic inhibitor activities</ce:section-title>
                     <ce:para id="p0070" view="all">All newly synthesized compounds were evaluated for their activity against JAK enzymes using a Homogenous Time-Resolved Fluorescence (HTRF) Kin EASE-TK assay system. For comparison, the activity of pan JAK inhibitor tofacitinib, was also evaluated using the same procedure.</ce:para>
                     <ce:para id="p0075" view="all">In this study, the inhibitory activity of newly synthesized compounds was evaluated using human JAK1, JAK2, JAK3, and TYK2 enzymes. To approach this optimization in a systematic fashion, this chemotype of target compounds was divided into four moieties, core (4, 6- or 2, 4-disubstituted pyrimidine), side chain (R<ce:inf loc="post">1</ce:inf>), tail (R<ce:inf loc="post">2</ce:inf>) and the linkage between core and tail. Furthermore, the side chain and tail varied sequentially. <ce:italic>In vitro</ce:italic>, the preliminary screening indicated that some derivatives showed good JAK3 inhibitory activity and selectivity compared with positive controls. The IC<ce:inf loc="post">50</ce:inf> values obtained in JAK enzyme assays are summarized in <ce:cross-refs id="crosrefs0035" refid="tbl2 tbl3">Tables 2 and 3</ce:cross-refs>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor>
                        <ce:float-anchor refid="tbl3"/></ce:float-anchor>.</ce:para>
                     <ce:para id="p0080" view="all">
                        <ce:italic>N</ce:italic>-methyl-6-(3-(substituted amino)phenyl)pyrimidin-4-amine derivatives (<ce:bold>1</ce:bold>–<ce:bold>6</ce:bold>, <ce:bold>13</ce:bold>–<ce:bold>29</ce:bold>) were synthesized with changes in the side chain (R<ce:inf loc="post">1</ce:inf>) and tail (R<ce:inf loc="post">2</ce:inf>). Several analogues using different ammonia groups (<ce:cross-ref id="crosref0230" refid="tbl2">Table 2</ce:cross-ref>) were generated to develop stronger JAK3 inhibitors, including compounds <ce:bold>1</ce:bold>–<ce:bold>6</ce:bold> that showed an IC<ce:inf loc="post">50</ce:inf> of 100–600 nM against JAK3. Next, to improve potency for JAK3, the SAR of the tail (R<ce:inf loc="post">2</ce:inf>) for compounds <ce:bold>13</ce:bold>–<ce:bold>29</ce:bold> was investigated (<ce:cross-ref id="crosref0235" refid="tbl3">Table 3</ce:cross-ref>). When butenamide groups were introduced (compounds <ce:bold>15</ce:bold> and <ce:bold>17</ce:bold>), both the inhibitory activities and selectivity for JAK3 increased up to 3-6-fold, when compared with compounds <ce:bold>2</ce:bold> and <ce:bold>3</ce:bold>. The resulting increase in inhibitory activities might be attributed to the length of the tail that covalently reacts with Cys909 in JAK3 kinases. Nevertheless, when the “length” of amide in compounds <ce:bold>15</ce:bold> and <ce:bold>17</ce:bold> was enhanced, creating compounds <ce:bold>23</ce:bold>–<ce:bold>29</ce:bold>, a decrease in inhibitory activities against JAK3 was observed. Therefore, <ce:italic>para</ce:italic>-substituted compounds <ce:bold>9</ce:bold>–<ce:bold>10</ce:bold> and <ce:bold>32</ce:bold>–<ce:bold>35</ce:bold> at the 4-position of the phenyl ring were designed for further modifications. The results showed that compounds showed a significant increase in inhibitory activities against JAK3.</ce:para>
                     <ce:para id="p0085" view="all">Replacement of 4,6-substituted pyrimidine with 2,4-substituted pyrimidine (compounds <ce:bold>7</ce:bold>–<ce:bold>8</ce:bold>, <ce:bold>11</ce:bold>–<ce:bold>12</ce:bold>, <ce:bold>30</ce:bold>–<ce:bold>31</ce:bold>, and <ce:bold>36</ce:bold>–<ce:bold>39</ce:bold>, <ce:cross-refs id="crosrefs0040" refid="tbl2 tbl3">Tables 2 and 3</ce:cross-refs>) retained the activities against JAK3 (inhibitory potency with an IC<ce:inf loc="post">50</ce:inf> ranging between 1.7 nM and 55 nM) and selectivity for JAK3 versus other kinases. Among this series, regarding the feature of the hydrophobic cavity, we mainly explored the side chain is 1-(2-methoxyethyl)-1<ce:italic>H</ce:italic>-pyrazol-4-amine or 4-morpholinoaniline. Compound <ce:bold>12</ce:bold> exhibited excellent inhibitory activity against JAK3 (IC<ce:inf loc="post">50</ce:inf> = 1.7 nM) and unprecedented selectivity (777-fold JAK1/3 and 588-fold JAK2/3), when compared to other derivatives. The results revealed that 4-morpholinoaniline (compounds <ce:bold>12</ce:bold> and <ce:bold>38</ce:bold>) have a higher potency compared to a pyrazole ring (<ce:bold>11</ce:bold> and <ce:bold>36</ce:bold>) at the 2-position of the pyrimidine ring. Compounds <ce:bold>12</ce:bold> (<ce:italic>C</ce:italic>log<ce:italic>P</ce:italic> = 3.77) and <ce:bold>38</ce:bold> (<ce:italic>C</ce:italic>log<ce:italic>P</ce:italic> = 4.02) exhibited a higher lipophilicity compared to compounds <ce:bold>11</ce:bold> and <ce:bold>36</ce:bold> (<ce:cross-ref id="crosref0240" refid="tbl4">Table 4</ce:cross-ref>
                        <ce:float-anchor refid="tbl4"/></ce:float-anchor>), respectively. The results demonstrated that the hydrophobic aromatic amine group improved the JAK3 inhibitory activity, which can be confirmed by molecular docking study where the hydrophobic aromatic amine group can create two σ-π interactions with amino acids Leu828 and Gly908 (<ce:cross-ref id="crosref0245" refid="fig3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>). After comparing the above-mentioned derivatives, we concluded that compounds with a <ce:italic>para</ce:italic>-acrylamide on the phenyl ring showed the greatest potency against JAK3 among others with <ce:italic>meta</ce:italic>-acrylamide. A similar trend was observed among other analogues with their parent compounds in 4,6-substituted pyrimidine derivatives. Based on the above-mentioned SAR, compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> were selected as tool compounds for additional studies.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Molecular docking study</ce:section-title>
                     <ce:para id="p0090" view="all">Based on the above discussion, compound <ce:bold>12</ce:bold> possessed the best inhibitory activities and selectivity for JAK3. To investigate the possible binding mode of compound <ce:bold>12</ce:bold> with JAK3 (PDB: <ce:inter-ref id="intref0010" xlink:href="pdb:4Z16" xlink:type="simple">4Z16</ce:inter-ref>), computer simulation of molecular docking is performed by Molecular Operating Environment (MOE) software. As shown in <ce:cross-ref id="crosref0250" refid="fig3">Fig. 3</ce:cross-ref>, the anilinopyrimidine moiety of compound <ce:bold>12</ce:bold> made the expected bidentate hinge hydrogen bonds with Leu905, and continuous electron density was observed between the acrylamide warhead and Cys909, indicative of covalent bond formation. The major difference in JAK3 binding models is that two σ-π interactions are produced by the morpholinoaniline of <ce:bold>12</ce:bold> with the amino acids Leu828 and Gly908 and a σ-π interaction between the pyrimidine core of <ce:bold>12</ce:bold> with the amino acid Leu828. Presumably, these interactions enhanced the activity of <ce:bold>12</ce:bold> against JAK3. Interestingly, the thiol group and Asp912 formed a hydrogen bond after the acryl group of compound <ce:bold>12</ce:bold> and the thiol group of residue Cys909 form a covalent bond, which indicated that compound <ce:bold>12</ce:bold> had tight contact with the ATP-binding pocket in JAK3. These docking observations reasonably explain the activity data.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Cell cytotoxicity evaluation</ce:section-title>
                     <ce:para id="p0095" view="all">To evaluate the effects of active compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> on the cell viability, resting mouse T cells, IL-4-treated activated T cells, and Raw 264.7 cells were used for the CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS assay). In general, resting T cells and IL-4-treated activated T cells do not have the ability to proliferate, but maintain normal survival. Raw 267.4 cells served as non-lymphocyte controls, and were selected for cytotoxicity evaluation. Treatment of the three cell types with compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> for 72 h at 10 μM, showed that three compounds did not have any influence on the three cell types (<ce:cross-ref id="crosref0255" refid="fig4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>). Taken together, these results indicated that the compounds had no obvious cytotoxicity against these cells when used at a concentration of 10 μM.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">Compounds on T cell proliferation <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0100" view="all">Based on the inhibitory potency and selectivity of compounds for JAK3, compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> were selected for further evaluation. In addition, their anti-proliferative activity against mouse T cell lines was assessed using the MTS assay. To analyze the immunosuppressive activity, mouse T cells were purified and activated with or without anti-CD3/-CD28 or IL-2 in the presence or absence of different concentrations of compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> for 72 h, then, the proliferation of T cells was analyzed by the MTS assay. As shown in <ce:cross-ref id="crosref0260" refid="tbl4">Table 4</ce:cross-ref>, compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> significantly suppressed T cell proliferation when stimulated by anti-CD3/CD28 with IC<ce:inf loc="post">50</ce:inf> values of 6.49, 0.83, and 1.60 μM or IL-2 with IC<ce:inf loc="post">50</ce:inf> value of 7.5, 0.77, and 2.11 μM, respectively. Especially, compound <ce:bold>12</ce:bold> displayed a stronger inhibition for T cell proliferation when compared to tofacitinib with an IC<ce:inf loc="post">50</ce:inf> value of 0.83 vs 1.38 (anti-CD3/CD28 stimulation) and 0.77 vs 1.54 (IL-2 stimulation), respectively. Together, our data demonstrated that compound <ce:bold>12</ce:bold> showed obvious significant immunosuppressive activity under selective inhibition of JAK3.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">Compound <ce:bold>12</ce:bold> selectively inhibits JAK3-dependent signaling in live cells</ce:section-title>
                     <ce:para id="p0105" view="all">To test whether the compounds were effective in a native cellular environment, we evaluated the ability of compounds to inhibit STAT5 phosphorylation in live cells using tofacitinib as a control. As shown in <ce:cross-ref id="crosref0265" refid="fig5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>, IL-2 or IL-15-induced STAT5 phosphorylation was significantly inhibited when used at a concentration of 10 μM after incubating mouse T cells with compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> for 1 h (<ce:cross-ref id="crosref0270" refid="fig5">Fig. 5</ce:cross-ref>A and B). Compared to the other two compounds and tofacitinib, compound <ce:bold>12</ce:bold> exhibited better inhibitory activity when used at the same concentration (10 μM). Further analysis indicated that compound <ce:bold>12</ce:bold> almost completely abrogated IL-2 or IL-15-induced phosphorylation of STAT5 at 1 μM treatment in a concentration-dependent manner (<ce:cross-ref id="crosref0275" refid="fig5">Fig. 5</ce:cross-ref>C and D). Data obtained from the cellular signaling pathway level further confirmed the selective activity of compound <ce:bold>12</ce:bold> on JAK3. Thus, these results demonstrated that compound <ce:bold>12</ce:bold> had potent inhibitory activity and selectivity on JAK3.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0070">Kinase selectivity profiling of compound <ce:bold>12</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0110" view="all">To further understand the selective kinase profile, the inhibitory effect of compound <ce:bold>12</ce:bold> for tyrosine kinases other than JAK family isoforms were evaluated, including BLK, BMX, BTK, EGFR, ERBB2, ERBB4, ITK, RLK, and TEC, which all carry a thiol in a position analogous to that of Cys909 in JAK3. The results are presented in <ce:cross-ref id="crosref0280" refid="tbl5">Table 5</ce:cross-ref>
                        <ce:float-anchor refid="tbl5"/></ce:float-anchor>, and show that compound <ce:bold>12</ce:bold> exhibited a potent inhibition rate of 100% for JAK3 at a concentration of 100 nM. However, the inhibition rate of the other 9 kinases was much lower than that of JAK3. Taken together, our data indicated that compound <ce:bold>12</ce:bold> exhibited a higher selective inhibition to JAK3 than other kinases with a cysteine at a position compared to that of Cys909.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0075">Compound <ce:bold>12</ce:bold> covalently binds to JAK3 and irreversibly inhibits JAK3</ce:section-title>
                     <ce:para id="p0115" view="all">To confirm that compound <ce:bold>12</ce:bold> irreversibly interacted with JAK3, a time-dependent inhibition assay was performed (<ce:cross-ref id="crosref0285" refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>A). For fair comparison, the concentration was performed at 2 nM at which compounds were profiled reflected their JAK3 potency. Extending the pre-treatment time of compound <ce:bold>12</ce:bold> with JAK3 improved the inhibitory effect, whereas the reversible inhibitor tofacitinib did not exhibit such time-dependent behavior (<ce:cross-ref id="crosref0290" refid="fig6">Fig. 6</ce:cross-ref>A). To further determining if compound <ce:bold>12</ce:bold> shared the features of irreversible inhibitors, the dissociation kinetics of compound <ce:bold>12</ce:bold> were evaluated. Compound <ce:bold>12</ce:bold> at an IC<ce:inf loc="post">90</ce:inf> (500 nM) was mixed and incubated with JAK3 for 30 min to allow complete association. This mixture was then diluted with kinase buffer 1000-fold to less than the IC<ce:inf loc="post">10</ce:inf>, and the enzymatic activity was evaluated via measuring the phosphorylated product by TR-FRET. The recovery rate of kinase activity related to JAK3 that had not been exposed to compound <ce:bold>12</ce:bold> was measured. Pre-treatment of JAK3 with compound <ce:bold>12</ce:bold> resulted in lack of any measurable JAK3 activity once the compound was diluted, suggesting that the inhibitor irreversibly bound to JAK3 for more than 24 h (<ce:cross-ref id="crosref0295" refid="fig6">Fig. 6</ce:cross-ref>B).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0080">Pharmacokinetic property evaluation</ce:section-title>
                     <ce:para id="p0120" view="all">Preliminary pharmacokinetic (PK) properties of compound <ce:bold>12</ce:bold> were performed in male ICR (Institute of Cancer Research) mice following intravenous and oral administration. The results are summarized in <ce:cross-ref id="crosref0300" refid="tbl6">Table 6</ce:cross-ref>
                        <ce:float-anchor refid="tbl6"/></ce:float-anchor> and the corresponding concentration-time curve was showed in <ce:cross-ref id="crosref0305" refid="appsec1">Fig. S1</ce:cross-ref> of supplementary material. Upon oral administration of 30 mg/kg, compound <ce:bold>12</ce:bold>, a reasonable PK profile was obtained with a t<ce:inf loc="post">1/2</ce:inf> of 1.52 h, area under curve (AUC) of 889.42 μg/L*h, and moderate bioavailability of 23.82%. These data suggested that compound <ce:bold>12</ce:bold> may be a useful probe for cellular and animal studies.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.10" view="all">
                     <ce:label>2.10</ce:label>
                     <ce:section-title id="sectitle0085">In vivo immunosuppressive activity</ce:section-title>
                     <ce:section id="sec2.10.1" view="all">
                        <ce:label>2.10.1</ce:label>
                        <ce:section-title id="sectitle0090">Compound <ce:bold>12</ce:bold> inhibited oxazolone-induced delayed type hypersensitivity reaction</ce:section-title>
                        <ce:para id="p0125" view="all">Delayed type hypersensitivity (DTH) reaction is a T cell-mediated pathologic response. To test the immunosuppressive activity of compounds <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>38</ce:bold> 
                           <ce:italic>in vivo</ce:italic>, the effects of these compounds on an oxazolone (OXZ)-induced DTH Balb/c mice model [<ce:cross-ref id="crosref0310" refid="bib30">30</ce:cross-ref>] were determined using tofacitinib as the positive control [<ce:cross-ref id="crosref0315" refid="bib31">31</ce:cross-ref>] (<ce:cross-ref id="crosref0320" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>A). Following sensitization by OXZ, mice were administrated compounds or tofacitinib by p.o. at a dose of 30 mg/kg. Ear swelling and spleen index were used to assess the effect of drugs. Following 7 days of administration, only compound <ce:bold>12</ce:bold> displayed a significant reduction of ear swelling by OXZ-induced DTH (<ce:cross-ref id="crosref0325" refid="fig7">Fig. 7</ce:cross-ref>B and C). In addition, all agents showed a reduction in the spleen index, and compound <ce:bold>12</ce:bold> and tofacitinib exhibited potent suppression (<ce:cross-ref id="crosref0330" refid="fig7">Fig. 7</ce:cross-ref>D). The spleen index is an important index to evaluate immunosuppression, and our data indicated that compound <ce:bold>12</ce:bold> exhibited obvious immunosuppressive activity.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.10.2" view="all">
                        <ce:label>2.10.2</ce:label>
                        <ce:section-title id="sectitle0095">Compound <ce:bold>12</ce:bold> inhibited dose-dependent OXZ-induced DTH responses</ce:section-title>
                        <ce:para id="p0130" view="all">To further evaluate the effect of compound <ce:bold>12</ce:bold> on OXZ-induced DTH responses, three doses of compound <ce:bold>12</ce:bold> were administered to OXZ-induced DTH mice. Our results indicated that in OXZ-induced DTH mice, compound <ce:bold>12</ce:bold> reduced edema of ear tissue in a dose-dependent manner (<ce:cross-ref id="crosref0335" refid="fig8">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>A and B). In addition, high doses of compound <ce:bold>12</ce:bold> and tofacitinib significantly inhibited the spleen index (<ce:cross-ref id="crosref0340" refid="fig8">Fig. 8</ce:cross-ref>C). Histopathological changes and inflammatory cell infiltration were evaluated by eosin and hematoxylin (HE) staining. HE-staining showed less neutrophil leukocyte infiltration and well-structured tissue architecture in the mice that were given compound <ce:bold>12</ce:bold> (30 mg/kg) when compared to the vehicle group (<ce:cross-ref id="crosref0345" refid="fig8">Fig. 8</ce:cross-ref>D), which showed significant dense neutrophil leukocyte infiltration and increased ear thickness. Upon oral administration of 30 mg/kg compound <ce:bold>12</ce:bold>, the neutrophil leukocyte infiltration was reduced and edema was decreased, and ear tissue was similar to that in control tissues.</ce:para>
                        <ce:para id="p0135" view="all">In addition, no signs of toxicity were observed in compound-treated mice based on body weight and microscopic examination of individual organs (data not shown).</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0100">Conclusion</ce:section-title>
                  <ce:para id="p0140" view="all">JAK is a confirmed pivotal target for immune and inflammatory diseases, and there is continuous interest in the discovery of novel selective inhibitors that overcome the side effects. In a recent study, novel derivatives were designed and synthesized based on 4- or 6-phenyl-pyrimidine as novel selective JAK3 inhibitors. After primary SAR analysis and enzymatic inhibitory activity <ce:italic>in vitro</ce:italic>, compound <ce:bold>12</ce:bold> showed a highly potent and selective inhibition for JAK3 with an IC<ce:inf loc="post">50</ce:inf> value of 1.7 nM, and exceeding 588-fold selectivity versus other enzymes in the JAK family. Molecular docking studies suggested that compound <ce:bold>12</ce:bold> might covalently bind to the Cys909 position of JAK3. T cell proliferation and kinase signal pathway experiments revealed that compound <ce:bold>12</ce:bold> presented a high selectivity within the JAK family. Further <ce:italic>in vivo</ce:italic> studies using an OXZ-induced DTH mouse model indicated that compound <ce:bold>12</ce:bold> had significant anti-inflammatory and immunosuppressive activities. Moreover, compound <ce:bold>12</ce:bold> possessed reasonable oral pharmacokinetic properties. Therefore, the data obtained in the current study suggested that compound <ce:bold>12</ce:bold> may be a promising tool compound for treating autoimmune diseases as a selective JAK3 inhibitor.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="materials-methods" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0105">Experimental procedures</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0110">Chemistry and chemical methods</ce:section-title>
                     <ce:para id="p0145" view="all">Unless specified otherwise, all starting materials, reagents, and solvents were commercially available and used without further purification. All chemicals or reagents were of analytical grade. Silica gel (200–300 mesh, Qingdao city, China) was used for column chromatography. The progress of reactions was monitored by analytical thin-layer chromatography (TLC) on silica gel plates (GF-254) and visualized under UV light at 254 or 365 nm. Melting points of individual compounds were determined using a Mel-TEMP II and melting point apparatus uncorrected. <ce:sup loc="post">1</ce:sup>H NMR and <ce:sup loc="post">13</ce:sup>C NMR spectra were recorded using a Bruker ARX-300 spectrometer with TMS as the internal standard in CDCl<ce:inf loc="post">3</ce:inf>, DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>. Peak multiplicities were abbreviated as follows: singlet, s; doublet, d; triplet, t; m, multiplet; dd, double doublet. Mass spectrum (MS) was obtained on an Agilent 6120 quadrupole LC/MS (ESI). High resolution mass spectrum (HRMS) was run on an Agilent Q-TOF mass spectrometer.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0115">4-Chloro-6-(3-nitrophenyl)pyrimidine (<ce:bold>40</ce:bold>)</ce:section-title>
                        <ce:para id="p0150" view="all">3-Bromonitrobenzene (1 g, 5.0 mmol), bis(pinacolato)diboron (1.34 g, 2.6 mmol), KOAc (1.48 g, 7.5 mmol), and Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (0.11 g, 0.09 mmol) were combined in 1,4-dioxane (50 mL). The reaction mixture was placed into an oil bath preheated to 100 °C, with stirring at this temperature for 12 h under argon. When completion of the reaction showed TLC, cooled to room temperature, respectively added to 2,6-dichloropyrimidine (1.07 g, 7.2 mmol), 2 M K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (2 g, 14.5 mmol) aqueous solution and Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (0.10 g, 0.09 mmol), heated to 100 °C in oil bath, stirred at this temperature for 12 h under argon. The reaction mixture was filtered through a Celite bed, and the filtrate was concentrated and purified by silica gel column chromatography (hexane: ethyl acetate = 50:1) to afford <ce:bold>40</ce:bold> as a white solid (0.82 g, total yield 68%). <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.11 (s, 1H), 8.95 (s, 1H), 8.45 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.41 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 7.85 (s, 1H), 7.74 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0120">4-Chloro-6-(4-nitrophenyl)pyrimidine (<ce:bold>43</ce:bold>)</ce:section-title>
                        <ce:para id="p0155" view="all">Compound <ce:bold>43</ce:bold> was prepared with the same procedures as for <ce:bold>40</ce:bold> as reported in 70% total yield. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.11 (s, 1H), 8.38 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 8.27 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 7.83 (s, 1H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0125">2-Chloro-4-(3-nitrophenyl)pyrimidine (<ce:bold>46</ce:bold>)</ce:section-title>
                        <ce:para id="p0160" view="all">Compound <ce:bold>46</ce:bold> was prepared with the same procedures as for <ce:bold>40</ce:bold> as reported in 81% total yield. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.92 (s, 1H), 8.76 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 8.48 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.40 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 7.76–7.73 (m, 2H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0130">2-Chloro-4-(4-nitrophenyl)pyrimidine (<ce:bold>49</ce:bold>)</ce:section-title>
                        <ce:para id="p0165" view="all">Compound <ce:bold>49</ce:bold> was prepared with the same procedures as for <ce:bold>40</ce:bold> as reported in 76% total yield. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.76 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 8.37 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 8.28 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 7.73 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0135">N-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenyl)pyrimidin-2-amine (<ce:bold>41a</ce:bold>)</ce:section-title>
                        <ce:para id="p0170" view="all">To <ce:bold>40</ce:bold> (0.2 g, 0.85 mmol) and 1-methyl-1<ce:italic>H</ce:italic>-pyrazol-4-amine hydrochloride salt (0.13 g, 0.94 mmol) in isopropyl alcohol (8 mL) was added <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>- diisopropylethylamine (DIEA, 0.27g, 2.13 mmol), and the mixture was stirred overnight at 110 °C. The mixture was then concentrated, and purified by column chromatography (DCM: MeOH = 40:1) to yield 0.21 g (82%) of <ce:bold>41a</ce:bold> as a light yellow solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.82 (s, 1H), 8.71 (s, 1H), 8.44 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 8.35 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 8.04 (s, 1H), 7.82 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.54 (s, 1H), 7.21 (s, 1H), 3.84 (s, 3H).</ce:para>
                        <ce:para id="p0175" view="all">Compounds <ce:bold>41b-f</ce:bold>, <ce:bold>44b-c</ce:bold>, <ce:bold>47b</ce:bold>-<ce:bold>c</ce:bold>, and <ce:bold>50b</ce:bold>-<ce:bold>c</ce:bold> were prepared following the similar synthetic procedure of compound <ce:bold>41a</ce:bold>. Detailed experimental procedure and spectral data are presented in the <ce:cross-ref id="crosref0350" refid="appsec1">supplementary material</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0140">4-(3-Aminophenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (<ce:bold>42a</ce:bold>)</ce:section-title>
                        <ce:para id="p0180" view="all">To <ce:bold>41a</ce:bold> (0.28g, 0.95 mmol) and 10% Pd/C 0.1g in EtOH (50 mL) was added drop by drop 85% hydrazine hydrate (0.47 g, 9.5 mmol) at 88 °C. The reaction mixture was stirred for 2h under nitrogen. The mixture was then filtered with a Celite bed, the filtrate was concentrated and dried under vacuum to yield 0.24 mg (95%) of <ce:bold>42a</ce:bold> as a white solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.60 (s, 1H), 8.00 (s, 1H), 7.50 (s, 1H), 7.26 (s, 1H), 7.12 (s, 2H), 6.97 (s, 1H), 6.80–6.56 (m, 1H), 3.83 (s, 3H).</ce:para>
                        <ce:para id="p0185" view="all">Compounds <ce:bold>42b-f</ce:bold>, <ce:bold>45b</ce:bold>-<ce:bold>c</ce:bold>, <ce:bold>4</ce:bold>8<ce:bold>b</ce:bold>-<ce:bold>c</ce:bold>, and <ce:bold>51b</ce:bold>-<ce:bold>c</ce:bold> were prepared following the similar synthetic procedure of compound <ce:bold>42a</ce:bold>. Detailed spectral data are presented in the <ce:cross-ref id="crosref0355" refid="appsec1">supplementary material</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title id="sectitle0145">
                           <ce:italic>Tert</ce:italic>-butyl(2-((3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) amino)-2-oxoethyl)carbamate (<ce:bold>52a</ce:bold>)</ce:section-title>
                        <ce:para id="p0190" view="all">To a solution of <ce:italic>N</ce:italic>-((2,2-dimethylpropoxy)carbonyl)-glycine (0.2 g, 1.13 mmol) in DCM (10 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 0.36 g, 1.88 mmol), 1-hydroxybenzotriazole (HOBT, 0.25 g, 1.88 mmol), and DIEA (0.34 g, 2.6 mmol) were added, respectively. And the mixture was stirred for 30 min at 0 °C. <ce:bold>42a</ce:bold> (0.2 g, 0.75 mmol) was added to the reaction mixture, then allowed to warm to room temperature with stirring for 6h. After completion of the reaction, the mixture was extracted with DCM, washed with brine, and the organic phase was dried over Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solvent was removed and the residue was purified by flash column chromatography on silica (DCM: MeOH = 30:1) to give a yellow solid (0.27g, 85%). <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.64 (s, 1H), 8.00 (s, 1H), 7.76 (s, 1H), 7.60 (s, 1H), 7.58 (s, 1H), 7.55 (s, 1H), 7.34–7.27 (m, 1H), 6.77 (s, 1H), 3.98 (d, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 3.90 (s, 3H), 1.46 (s, 9H).</ce:para>
                        <ce:para id="p0195" view="all">Compounds <ce:bold>52b</ce:bold>-<ce:bold>c</ce:bold> and <ce:bold>52e</ce:bold> were prepared following the similar synthetic procedure of compound <ce:bold>52a</ce:bold>. Detailed spectral data are presented in the <ce:cross-ref id="crosref0360" refid="appsec1">supplementary material</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.8" view="all">
                        <ce:label>4.1.8</ce:label>
                        <ce:section-title id="sectitle0150">2-Amino-N-(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acetamide (<ce:bold>53a</ce:bold>)</ce:section-title>
                        <ce:para id="p0200" view="all">To a solution containing <ce:bold>52a</ce:bold> (0.5 g, 1.34 mmol) in 2 mL of dry DCM, cooled to 0 °C was slowly added TFA (2 mL, 13 mmol). After the consumption of the starting material (5 h, monitored by TLC), the solvent was evaporated, and removed under vacuum. Semi-solid was slurred with dry ether, and filtered to afford crude product (0.36 g, 98%), which was used directly in the next step.</ce:para>
                        <ce:para id="p0205" view="all">Compounds <ce:bold>53b</ce:bold>-<ce:bold>c</ce:bold> and <ce:bold>53e</ce:bold> were prepared following the similar synthetic procedure of compound <ce:bold>53a</ce:bold>. Detailed spectral data are presented in the <ce:cross-ref id="crosref0365" refid="appsec1">supplementary material</ce:cross-ref>.</ce:para>
                        <ce:para id="p0210" view="all">
                           <ce:bold>Method A</ce:bold>: General procedure for the synthesis of targets <ce:bold>1</ce:bold>–<ce:bold>12</ce:bold>, <ce:bold>13</ce:bold>, <ce:bold>15</ce:bold>, <ce:bold>17</ce:bold>, <ce:bold>19</ce:bold>–<ce:bold>21</ce:bold>, <ce:bold>24</ce:bold>–<ce:bold>27</ce:bold>, <ce:bold>30</ce:bold>, <ce:bold>32</ce:bold>, <ce:bold>34</ce:bold>, <ce:bold>36</ce:bold>, and <ce:bold>38</ce:bold>.</ce:para>
                        <ce:para id="p0215" view="all">To a solution of <ce:bold>42a</ce:bold> (0.1 g, 0.37 mmol) in THF (5 mL) were added DIEA (0.05g, 0.37 mmol) and acryloyl chloride (0.03g, 0.37 mmol) at −5 °C. The resulting mixture was stirred for 30 min. Then it was quenched by MeOH (2 mL), concentrated, and purified by silica gel column chromatography (DCM: MeOH = 20:1) to afford the title compounds.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.9" view="all">
                        <ce:label>4.1.9</ce:label>
                        <ce:section-title id="sectitle0155">N-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>1</ce:bold>)</ce:section-title>
                        <ce:para id="p0220" view="all">White solid (yield: 71%). m. p.: 214–216 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.65 (s, 1H), 8.44 (s, 1H), 8.01 (s, 1H), 7.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.52 (s, 1H), 7.46 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.07 (s, 1H), 6.47 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.32–6.26 (m, 1H), 5.80–5.75 (m, 1H), 3.84 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.35, 160.38, 158.48, 139.52, 137.60, 131.79, 130.66, 129.26, 127.01, 122.03, 121.44, 120.96, 117.41, 104.10, 100.75, 38.72; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">6</ce:inf>O [M+H]<ce:sup loc="post">+</ce:sup> 321.1461, found 321.1460.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.10" view="all">
                        <ce:label>4.1.10</ce:label>
                        <ce:section-title id="sectitle0160">N-(3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>2</ce:bold>)</ce:section-title>
                        <ce:para id="p0225" view="all">White solid (yield: 72%). m. p.: 213–215 °C. 213.2–215.1 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.69 (s, 1H), 8.48 (s, 1H), 8.06 (s, 1H), 7.81 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.59 (s, 1H), 7.47 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.10 (s, 1H), 6.49 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.31 (d, <ce:italic>J</ce:italic> = 16.7 Hz, 1H), 5.78 (d, <ce:italic>J</ce:italic> = 10.6 Hz, 1H), 4.25 (t, <ce:italic>J</ce:italic> = 4.9 Hz, 2H), 3.68 (t, <ce:italic>J</ce:italic> = 4.9 Hz, 2H), 3.23 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.31, 160.23, 158.52, 139.54, 137.56, 131.77, 130.61, 129.26, 127.03, 121.88, 121.38, 120.91, 117.34, 101.03, 70.65, 57.92, 51.33; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 365.1882, found 365.1880.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.11" view="all">
                        <ce:label>4.1.11</ce:label>
                        <ce:section-title id="sectitle0165">N-(3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>3</ce:bold>)</ce:section-title>
                        <ce:para id="p0230" view="all">White solid (yield: 74%). m. p.: 224–225 °C. 223.7–225.1 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.62 (s, 1H), 8.45 (s, 1H), 7.80 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 7.46 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.15 (s, 1H), 6.95 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.50 (dd, <ce:italic>J</ce:italic> = 16.6, 10.2 Hz, 1H), 6.29 (d, <ce:italic>J</ce:italic> = 17.0 Hz, 1H), 5.78 (d, <ce:italic>J</ce:italic> = 10.1 Hz, 1H), 3.74 (s, 4H), 3.06 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.82, 161.63, 161.06, 158.77, 147.52, 140.04, 138.10, 132.27, 129.75, 127.48, 122.07, 121.85, 121.43, 117.80, 116.14, 101.63, 66.60, 49.04; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 402.1926, found 402.1924.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.12" view="all">
                        <ce:label>4.1.12</ce:label>
                        <ce:section-title id="sectitle0170">N-(3-(6-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)acrylamide (<ce:bold>4</ce:bold>)</ce:section-title>
                        <ce:para id="p0235" view="all">White solid (yield: 65%). m. p.: 198–199 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.66 (s, 1H), 8.47 (s, 1H), 8.06 (s, 1H), 7.80 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 7.55 (s, 1H), 7.47 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.09 (s, 1H), 6.49 (dd, <ce:italic>J</ce:italic> = 16.7, 10.0 Hz, 1H), 6.30 (d, <ce:italic>J</ce:italic> = 17.1 Hz, 1H), 5.78 (d, <ce:italic>J</ce:italic> = 10.0 Hz, 1H), 4.18 (s, 2H), 2.63 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.16 (s, 6H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.27, 160.01, 158.51, 149.03, 139.56, 137.54, 131.79, 129.27, 127.02, 121.32, 120.86, 117.27, 101.01, 58.71, 49.61, 45.11; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">7</ce:inf>O [M+H]<ce:sup loc="post">+</ce:sup> 378.2044, found 378.2041.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.13" view="all">
                        <ce:label>4.1.13</ce:label>
                        <ce:section-title id="sectitle0175">N-(3-(6-((1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)amino)pyrimidin- 4-yl)phenyl)acrylamide (<ce:bold>5</ce:bold>)</ce:section-title>
                        <ce:para id="p0240" view="all">White solid (yield: 66%). m. p.: 244–245 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.68 (s, 1H), 8.47 (s, 1H), 8.09 (s, 1H), 7.81 (d, <ce:italic>J</ce:italic> = 3.5 Hz, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 7.58 (s, 1H), 7.47 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.11 (s, 1H), 6.50 (dd, <ce:italic>J</ce:italic> = 16.4, 9.7 Hz, 1H), 6.30 (d, <ce:italic>J</ce:italic> = 16.9 Hz, 1H), 5.79 (d, <ce:italic>J</ce:italic> = 9.8 Hz, 1H), 4.77 (s, 2H), 2.62 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 167.17, 163.29, 160.19, 158.50, 154.37, 139.57, 137.52, 131.80, 129.27, 127.01, 121.35, 120.90, 117.30, 54.29, 25.56; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">7</ce:inf>NaO<ce:inf loc="post">2</ce:inf> [M+Na]<ce:sup loc="post">+</ce:sup> 400.1496, found 400.1498.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.14" view="all">
                        <ce:label>4.1.14</ce:label>
                        <ce:section-title id="sectitle0180">N-(3-(6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>6</ce:bold>)</ce:section-title>
                        <ce:para id="p0245" view="all">White solid (yield: 65%). m. p.: 211–213 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.83 (s, 1H), 8.13 (s, 1H), 7.89 (s, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 3.3 Hz, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.53 (s, 1H), 7.49–7.43 (m, 1H), 7.26 (s, 1H), 6.63 (dd, <ce:italic>J</ce:italic> = 16.9, 10.1 Hz, 1H), 6.29 (d, <ce:italic>J</ce:italic> = 16.8 Hz, 1H), 5.77 (d, <ce:italic>J</ce:italic> = 10.2 Hz, 1H), 4.16 (s, 2H), 3.73 (s, 2 H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.58, 159.26, 154.57, 154.11, 140.05, 132.98, 131.73, 130.19, 129.68, 127.13, 122.47, 122.07, 120.76, 117.53, 116.91, 102.79, 60.03, 54.40; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">6</ce:inf>NaO<ce:inf loc="post">2</ce:inf> [M+Na]<ce:sup loc="post">+</ce:sup> 373.1379, found 373.1377.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.15" view="all">
                        <ce:label>4.1.15</ce:label>
                        <ce:section-title id="sectitle0185">N-(3-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>7</ce:bold>)</ce:section-title>
                        <ce:para id="p0250" view="all">White solid (yield: 69%). m. p.: 189–190 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.84 (s, 1H), 8.47 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 8.21 (s, 1H), 7.79 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 7.65 (s, 1H), 7.54 (s, 1H), 7.47 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 4.6 Hz, 1H), 6.54 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 16.9 Hz, 1H), 5.78 (d, <ce:italic>J</ce:italic> = 10.3 Hz, 1H), 4.33 (s, 2H), 3.70 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 3.23 (s,3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.42, 159.58, 159.02, 139.60, 137.43, 131.87, 129.88, 129.09, 126.79, 123.02, 121.88, 121.44, 120.09, 117.78, 106.44, 70.83, 57.86, 50.98; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 365.1716, found 365.1711.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.16" view="all">
                        <ce:label>4.1.16</ce:label>
                        <ce:section-title id="sectitle0190">N-(3-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>8</ce:bold>)</ce:section-title>
                        <ce:para id="p0255" view="all">White solid (yield: 74%). m. p.: 221–224 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.55 (s, 1H), 8.50 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 7.82 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 7.69 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 7.49 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 6.98 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 6.51 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 16.8 Hz, 1H), 5.80 (d, <ce:italic>J</ce:italic> = 11.4 Hz, 1H), 3.76 (s, 4H), 3.07 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.47, 163.30, 160.25, 158.90, 139.54, 137.47, 131.83, 129.22, 126.95, 122.00, 121.58, 120.20, 117.87, 115.93, 107.24, 66.05, 49.50; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 402.1928, found 402.1924.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.17" view="all">
                        <ce:label>4.1.17</ce:label>
                        <ce:section-title id="sectitle0195">N-(4-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>9</ce:bold>)</ce:section-title>
                        <ce:para id="p0260" view="all">White solid (yield: 78%). m. p.: 191–193 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.01 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 3H), 7.82 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.55 (s, 1H), 7.04 (s, 1H), 6.48 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.30 (d, <ce:italic>J</ce:italic> = 16.5 Hz, 1H), 5.79 (d, <ce:italic>J</ce:italic> = 10.1 Hz, 1H), 4.25 (t, <ce:italic>J</ce:italic> = 4.9 Hz, 2H), 3.69 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.24 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.32, 160.14, 158.44, 140.83, 131.89, 131.72, 131.04, 127.20, 127.03, 125.78, 121.92, 120.19, 119.26, 117.41, 99.78, 70.66, 57.94, 51.31; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 365.1725, found 365.1721.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.18" view="all">
                        <ce:label>4.1.18</ce:label>
                        <ce:section-title id="sectitle0200">N-(4-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>10</ce:bold>)</ce:section-title>
                        <ce:para id="p0265" view="all">White solid (yield: 80%). m. p.: 248–250 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.60 (s, 1H), 7.98 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.82 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.51 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.09 (s, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 6.48 (dd, <ce:italic>J</ce:italic> = 16.6, 10.1 Hz, 1H), 6.29 (d, <ce:italic>J</ce:italic> = 16.8 Hz, 1H), 5.79 (d, <ce:italic>J</ce:italic> = 9.8 Hz, 1H), 3.74 (s, 4H), 3.06 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.32, 161.10, 160.22, 158.16, 147.03, 140.87, 131.81, 131.71, 128.61, 127.21, 127.01, 121.67, 119.28, 115.65, 100.19, 66.11, 48.97; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 402.1923, found 402.1926.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.19" view="all">
                        <ce:label>4.1.19</ce:label>
                        <ce:section-title id="sectitle0205">N-(4-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) acrylamide (<ce:bold>11</ce:bold>)</ce:section-title>
                        <ce:para id="p0270" view="all">White solid (yield: 76%). m. p.: 201–203 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.43 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 8.15 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 8.02 (s, 1H), 7.88 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.60 (s, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 6.52 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 16.9 Hz, 1H), 5.79 (d, <ce:italic>J</ce:italic> = 10.2 Hz, 1H), 4.26 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.69 (t, <ce:italic>J</ce:italic> = 5.1 Hz, 2H), 3.27 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.88, 163.62, 160.16, 159.25, 141.86, 132.17, 130.53, 127.99, 127.74, 123.61, 120.59, 119.71, 106.52, 71.29, 58.41, 51.74; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 365.1712, found 365.1717.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.20" view="all">
                        <ce:label>4.1.20</ce:label>
                        <ce:section-title id="sectitle0210">N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acrylamide (<ce:bold>12</ce:bold>)</ce:section-title>
                        <ce:para id="p0275" view="all">White solid (yield: 82%). m. p.: 210–212 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.45 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 8.15 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.86 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.69 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 7.28 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 6.93 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 6.51 (dd, <ce:italic>J</ce:italic> = 16.9, 10.0 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 16.8 Hz, 1H), 5.80 (d, <ce:italic>J</ce:italic> = 11.6 Hz, 1H), 3.79–3.70 (m, 4H), 3.08–3.02 (m, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.43, 162.95, 160.32, 158.69, 146.10, 141.43, 133.10, 131.75, 127.56, 127.31, 120.23, 119.25, 115.67, 106.65, 66.20, 49.34; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 402.1928, found 402.1924.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.21" view="all">
                        <ce:label>4.1.21</ce:label>
                        <ce:section-title id="sectitle0215">N-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)but-2-enam ide (<ce:bold>13</ce:bold>)</ce:section-title>
                        <ce:para id="p0280" view="all">White solid (yield: 80%). m. p.: 193–196 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.84 (s, 1H), 8.35 (s, 1H), 8.10 (s, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 7.71 (s, 1H), 7.58 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 7.55–7.51 (m, 1H), 7.25 (s, 1H), 6.92–6.73 (m, 1H), 6.28 (d, <ce:italic>J</ce:italic> = 15.1 Hz, 1H), 3.85 (s, 3H), 1.85 (d, <ce:italic>J</ce:italic> = 4.9 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.89, 159.14, 153.31, 151.38, 140.40, 140.28, 131.19, 130.64, 129.68, 125.80, 122.90, 122.62, 121.83, 120.19, 117.35, 103.01, 54.89, 17.50; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">6</ce:inf>O [M+H]<ce:sup loc="post">+</ce:sup> 335.1615, found 335.1618.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.22" view="all">
                        <ce:label>4.1.22</ce:label>
                        <ce:section-title id="sectitle0220">N-(3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>15</ce:bold>)</ce:section-title>
                        <ce:para id="p0285" view="all">White solid (yield: 82%). m. p.: 188–190 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.87 (s, 1H), 8.37 (s, 1H), 8.13 (s, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 7.76 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 7.54 (t, <ce:italic>J</ce:italic> = 7.6 Hz,1H), 7.25 (s, 1H), 6.92–6.73 (m, 1H), 6.28 (d, <ce:italic>J</ce:italic> = 15.1 Hz, 1H), 4.28 (t, <ce:italic>J</ce:italic> = 4.9 Hz, 2H), 3.68 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.23 (s, 3H). 1.86 (d, <ce:italic>J</ce:italic> = 5.0 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.89, 159.24, 153.47, 140.41, 140.33, 131.45, 130.78, 129.73, 125.81, 122.62, 121.85, 120.08, 117.37, 103.04, 70.47, 57.96, 51.50, 17.52; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 379.1886, found 379.1881.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.23" view="all">
                        <ce:label>4.1.23</ce:label>
                        <ce:section-title id="sectitle0225">N-(3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>17</ce:bold>)</ce:section-title>
                        <ce:para id="p0290" view="all">White solid (yield: 85%). m. p.: 257–259 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.43 (s, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.68 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.44 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.12 (s, 1H), 6.95 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 6.84 (dt, <ce:italic>J</ce:italic> = 21.0, 7.2 Hz, 1H), 6.16 (d, <ce:italic>J</ce:italic> = 15.2 Hz, 1H), 3.74 (s, 4H), 3.06 (s, 4H), 1.88 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 164.10, 161.65, 161.17, 158.77, 147.53, 140.49, 140.33, 138.07, 132.20, 129.68, 126.45, 122.10, 121.53, 121.32, 117.68, 116.14, 101.54, 66.60, 49.47, 17.97; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 416.2084, found 416.2088.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.24" view="all">
                        <ce:label>4.1.24</ce:label>
                        <ce:section-title id="sectitle0230">N-(3-(6-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)but-2-enamide (<ce:bold>19</ce:bold>)</ce:section-title>
                        <ce:para id="p0295" view="all">White solid (yield: 66%). m. p.: 197–199 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.60 (s, 2H), 8.05 (s, 1H), 7.84 (s,2H), 7.65 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 9.5 Hz, 2H), 7.22 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 6.95 (td, <ce:italic>J</ce:italic> = 13.7, 6.6 Hz, 1H), 6.71 (s, 1H), 5.99 (d, <ce:italic>J</ce:italic> = 15.1 Hz, 1H), 4.18 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 2.75 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 2.24 (s, 6H), 1.80 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 164.85, 162.11, 161.37, 158.40, 141.64, 138.77, 137.98, 133.00, 129.26, 125.41, 123.32, 122.55, 122.02, 118.52, 100.85, 58.90, 50.47, 45.40, 17.79; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">7</ce:inf>O [M+H]<ce:sup loc="post">+</ce:sup> 392.2194, found 392.2196.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.25" view="all">
                        <ce:label>4.1.25</ce:label>
                        <ce:section-title id="sectitle0235">N-(3-(6-((1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)amino)pyrimidin -4-yl)phenyl)but-2-enami-de (<ce:bold>20</ce:bold>)</ce:section-title>
                        <ce:para id="p0300" view="all">White solid (yield: 66%). m. p.: 224–227 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.89 (s, 1H), 8.32 (d, <ce:italic>J</ce:italic> = 29.2 Hz, 2H), 8.18 (s, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 5.4 Hz, 1H), 7.77 (s, 1H), 7.56 (d, <ce:italic>J</ce:italic> = 12.0 Hz, 2H), 7.28 (s, 1H), 6.83 (dt, <ce:italic>J</ce:italic> = 13.5, 5.3 Hz, 1H), 6.28 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.84 (s, 2H), 2.62 (s, 3H), 1.86 (d, <ce:italic>J</ce:italic> = 4.5 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 166.87, 163.89, 159.09, 153.24, 151.11, 140.41, 131.76, 130.43, 129.77, 125.76, 123.67, 122.67, 121.88, 120.19, 117.33, 103.15, 66.97, 25.53, 17.54; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">7</ce:inf>NaO<ce:inf loc="post">2</ce:inf> [M+Na]<ce:sup loc="post">+</ce:sup> 414.1645, found 414.1648.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.26" view="all">
                        <ce:label>4.1.26</ce:label>
                        <ce:section-title id="sectitle0240">N-(3-(6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>21</ce:bold>)</ce:section-title>
                        <ce:para id="p0305" view="all">White solid (yield: 64%). m. p.: 242–244 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.87 (s, 1H), 8.36 (s, 1H), 8.15 (s, 1H), 7.87 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.75 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 7.57–7.49 (m, 1H), 7.28 (s, 1H), 6.83 (dt, <ce:italic>J</ce:italic> = 22.5, 7.1 Hz, 1H), 6.29 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 4.17 (s, 2H), 3.74 (s, 2H), 1.86 (d, <ce:italic>J</ce:italic> = 6.5 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.90, 159.14, 153.45, 151.52, 140.37, 131.26, 130.80, 129.74, 125.77, 122.61, 121.82, 119.94, 117.36, 103.06, 59.99, 55.97, 18.49; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 365.1715, found 365.1719.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.27" view="all">
                        <ce:label>4.1.27</ce:label>
                        <ce:section-title id="sectitle0245">N-(2-((3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)amino)-2-oxoethyl)acrylamide (<ce:bold>24</ce:bold>)</ce:section-title>
                        <ce:para id="p0310" view="all">White solid (yield: 62%). m. p.: 198–199 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.83 (s, 1H), 8.57 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 2H), 7.63–7.53 (m, 2H), 7.49 (s, 1H), 6.33 (dd, <ce:italic>J</ce:italic> = 15.2, 8.2 Hz, 1H), 6.12 (d, <ce:italic>J</ce:italic> = 16.8 Hz, 1H), 5.63 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 4.28 (s, 2H), 4.04 (s, 2H)., 3.68 (s, 2H), 3.23 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 168.16, 165.06, 159.46, 154.41, 139.83, 132.17, 131.37, 129.81, 125.62, 122.47, 122.17, 121.85, 117.30, 102.82, 70.49, 57.96, 51.46, 42.74; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">3</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 422.1946, found 422.1941.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.28" view="all">
                        <ce:label>4.1.28</ce:label>
                        <ce:section-title id="sectitle0250">N-(2-((3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)amino)-2-oxoethyl) but-2-enamide (<ce:bold>25</ce:bold>)</ce:section-title>
                        <ce:para id="p0315" view="all">White solid (yield: 66%). m. p.: 185–188 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.86 (s, 1H), 8.39 (s, 1H), 8.24 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 8.12 (s, 1H), 7.77 (s, 1H), 7.74 (s, 1H), 7.59 (s, 1H),7.56 (s, 1H), 7.23 (s, 1H), 6.65 (s, 1H), 6.04 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1H), 4.28 (s, 2H), 3.94 (d, <ce:italic>J</ce:italic> = 36.3 Hz, 2H)., 3.68 (s, 2H), 3.23 (s, 3H), 1.77 (d, <ce:italic>J</ce:italic> = 17.6 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 168.41, 165.35, 165.22, 159.36, 153.91, 139.91, 139.24, 138.24, 131.44, 129.94, 129.80, 125.51, 122.52, 122.34, 121.88, 117.31, 102.98, 70.48, 57.96, 51.48, 42.74, 17.35; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">3</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 436.2098, found 436.2090.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.29" view="all">
                        <ce:label>4.1.29</ce:label>
                        <ce:section-title id="sectitle0255">N-(2-((3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)amino)-2- oxoethyl)acrylamide (<ce:bold>26</ce:bold>)</ce:section-title>
                        <ce:para id="p0320" view="all">White solid (yield: 63%). m. p.: 243–245 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.64 (s, 1H), 8.52 (s, 1H), 8.37 (s, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 3.9 Hz, 2H), 7.53 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 7.51–7.39 (m, 1H), 7.12 (s, 1H), 6.96 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 6.37 (dd, <ce:italic>J</ce:italic> = 15.6, 8.4 Hz, 1H), 6.13 (d, <ce:italic>J</ce:italic> = 16.8 Hz, 1H), 5.65 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 4.01 (s, 2H), 3.74 (s, 4H), 3.06 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 167.85, 165.04, 161.07, 158.18, 146.99, 139.42, 137.39, 131.63, 131.38, 129.31, 125.58, 121.52, 121.12, 120.73, 117.04, 115.63, 101.11, 66.08, 55.98, 42.72; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 459.2144, found 459.2146.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.30" view="all">
                        <ce:label>4.1.30</ce:label>
                        <ce:section-title id="sectitle0260">N-(2-((3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)amino)-2- oxoethyl)but-2-enamide (<ce:bold>27</ce:bold>)</ce:section-title>
                        <ce:para id="p0325" view="all">White solid (yield: 65%). m. p.: 236–237 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.36 (s, 1H), 8.20 (s, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 1.2 Hz, 2H), 7.52 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.45 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.12 (s, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 6.76–6.60 (m, 1H), 6.05 (d, <ce:italic>J</ce:italic> = 15.3 Hz, 1H), 3.99 (d, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 3.74 (s, 4H), 3.06 (s, 4H), 1.82 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 168.04, 165.40, 161.18, 160.67, 158.29, 147.06, 139.41, 138.22, 137.62, 131.69, 129.21, 125.57, 121.66, 121.14, 120.79, 117.21, 115.65, 101.04, 66.11, 48.99, 42.77, 17.30; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">6</ce:inf>NaO<ce:inf loc="post">3</ce:inf> [M+Na]<ce:sup loc="post">+</ce:sup> 495.2117, found 495.2118.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.31" view="all">
                        <ce:label>4.1.31</ce:label>
                        <ce:section-title id="sectitle0265">N-(3-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>30</ce:bold>)</ce:section-title>
                        <ce:para id="p0330" view="all">White solid (yield: 83%). m. p.: 264–265 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.49 (s, 1H), 7.87 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 7.77 (s, 3H), 7.44 (s, 1H), 7.22 (s, 1H), 7.16 (s, 1H), 6.97–6.72 (m, 2H), 6.38 (d, <ce:italic>J</ce:italic> = 14.6 Hz, 1H), 3.81 (s, 4H), 3.15 (s, 4H), 1.84 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.80, 163.72, 160.03, 158.77, 144.04, 140.10, 139.57, 137.14, 129.04, 126.23, 123.35, 121.56, 120.05, 117.80, 117.20, 107.52, 65.49, 50.49, 17.50; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 416.2084, found 416.2080.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.32" view="all">
                        <ce:label>4.1.32</ce:label>
                        <ce:section-title id="sectitle0270">N-(4-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>32</ce:bold>)</ce:section-title>
                        <ce:para id="p0335" view="all">White solid (yield: 84%). m. p.: 219–220 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.02 (d, <ce:italic>J</ce:italic> = 5.5 Hz, 2H), 7.98 (s, 1H), 7.80 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.56 (s, 1H), 7.04 (s, 1H), 6.84 (dq, <ce:italic>J</ce:italic> = 13.8, 6.7 Hz, 1H), 6.17 (d, <ce:italic>J</ce:italic> = 15.2 Hz, 1H), 4.25 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 3.68 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 3.24 (s, 3H), 1.87 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.61, 160.17, 158.40, 141.13, 140.24, 131.54, 130.94, 126.94, 125.86, 121.89, 121.55, 119.10, 99.68, 70.63, 57.90, 51.29, 17.44; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 379.1877, found 379.1878.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.33" view="all">
                        <ce:label>4.1.33</ce:label>
                        <ce:section-title id="sectitle0275">N-(4-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>34</ce:bold>)</ce:section-title>
                        <ce:para id="p0340" view="all">White solid (yield: 86%). m. p.: 276–277 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.59 (s, 1H), 7.97 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.80 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.51 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.08 (s, 1H), 6.93 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.83 (dt, <ce:italic>J</ce:italic> = 14.0, 7.0 Hz, 1H), 6.16 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 3.76–3.71 (m, 4H), 3.08–3.02 (m, 4H), 1.88 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.62, 161.08, 160.42, 158.22, 146.97, 141.14, 140.27, 131.75, 131.60, 126.92, 125.86, 121.63, 119.12, 115.63, 100.08, 66.09, 48.97, 17.46; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 416.2080, found 416.2087.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.34" view="all">
                        <ce:label>4.1.34</ce:label>
                        <ce:section-title id="sectitle0280">N-(4-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) but-2-enamide (<ce:bold>36</ce:bold>)</ce:section-title>
                        <ce:para id="p0345" view="all">White solid (yield: 85%). m. p.: 212–215 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.93 (d, <ce:italic>J</ce:italic> = 5.7 Hz, 1H), 8.18 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 8.07 (s, 1H), 7.96 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.68 (s, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 5.3 Hz, 1H), 6.82 (dt, <ce:italic>J</ce:italic> = 13.5, 6.7 Hz, 1H), 6.33 (d, <ce:italic>J</ce:italic> = 15.2 Hz, 1H), 4.30 (s, 2H), 3.69 (s, 2H), 3.26 (s, 3H), 1.85 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 164.06, 155.35, 153.58, 144.11, 140.69, 140.55, 129.20, 128.66, 127.88, 125.88, 124.03, 119.26, 119.14, 105.95, 70.57, 58.00, 51.46, 17.53; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 379.1882, found 379.1885.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.35" view="all">
                        <ce:label>4.1.35</ce:label>
                        <ce:section-title id="sectitle0285">N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)but-2-enamide (<ce:bold>38</ce:bold>)</ce:section-title>
                        <ce:para id="p0350" view="all">White solid (yield: 86%). m. p.: 268–271 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.42 (s, 1H), 8.12 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 7.83 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.68 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 7.25 (s, 1H), 6.92 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 6.83 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 6.17 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 3.73 (s, 4H), 3.03 (s, 4H), 1.88 (d, <ce:italic>J</ce:italic> = 4.7 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 164.17, 163.44, 160.75, 159.06, 146.54, 142.16, 140.87, 133.55, 131.78, 127.93, 126.33, 120.67, 119.55, 116.10, 107.03, 66.63, 49.78, 17.95; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 416.2080, found 416.2084.</ce:para>
                        <ce:para id="p0355" view="all">
                           <ce:bold>Method B</ce:bold>: General procedure for the synthesis of targets <ce:bold>14</ce:bold>, <ce:bold>16</ce:bold>, <ce:bold>18</ce:bold>, <ce:bold>22</ce:bold>–<ce:bold>23</ce:bold>, <ce:bold>28</ce:bold>–<ce:bold>29</ce:bold>, <ce:bold>31</ce:bold>, <ce:bold>33</ce:bold>, <ce:bold>35</ce:bold>, <ce:bold>37</ce:bold>, and <ce:bold>39</ce:bold>.</ce:para>
                        <ce:para id="p0360" view="all">To a stirred solution of <ce:bold>42a</ce:bold> (0.1 g, 0.37 mmol) in THF (15 mL) were added DIEA (0.12 g, 0.94 mmol), o-(7-azabenzotriazol-1-yl)<ce:italic>-N</ce:italic>,<ce:italic>N</ce:italic>,<ce:italic>N′</ce:italic>,<ce:italic>N′</ce:italic>-tetramethyluronium hexafluorophosphate (HATU, 0.35 g, 0.94 mmol), and 2-cyanoacetic acid (0.03 g, 0.41 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. It was quenched with water and extracted with ethyl acetate. The organic layer was washed with water followed by brine, dried over anhydrous sodium sulfate, and was evaporated to dryness. The crude mass was purified by silica gel column chromatography (DCM: MeOH = 20:1) to afford the title compounds.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.36" view="all">
                        <ce:label>4.1.36</ce:label>
                        <ce:section-title id="sectitle0290">2-Cyano-N-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)ace tamide (<ce:bold>14</ce:bold>)</ce:section-title>
                        <ce:para id="p0365" view="all">White solid (yield: 95%). m. p.: 193–195 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.66 (s, 1H), 8.33 (s, 1H), 8.02 (s, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 7.53 (s, 1H), 7.47 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.07 (s, 1H), 3.94 (s, 2H), 3.83 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 161.27, 158.28, 138.89, 137.40, 129.47, 121.78, 120.84, 117.15, 115.84, 56.00, 26.79; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">7</ce:inf>O [M+H]<ce:sup loc="post">+</ce:sup> 334.1419, found 334.1414.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.37" view="all">
                        <ce:label>4.1.37</ce:label>
                        <ce:section-title id="sectitle0295">2-Cyano-N-(3-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)acetamide (<ce:bold>16</ce:bold>)</ce:section-title>
                        <ce:para id="p0370" view="all">White solid (yield: 94%). m. p.: 186–188 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.66 (s, 1H), 8.34 (s, 1H), 8.03 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.56 (s, 1H), 7.47 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.07 (s, 1H), 4.25 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.94 (s, 2H), 3.68 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.23 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 161.71, 160.71, 159.01, 139.36, 138.16, 131.34, 129.89, 122.26, 121.31, 117.73, 116.27, 101.44, 71.13, 58.40, 51.82, 27.23; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 378.1676, found 378.1673.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.38" view="all">
                        <ce:label>4.1.38</ce:label>
                        <ce:section-title id="sectitle0300">2-Cyano-N-(3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acetami de (<ce:bold>18</ce:bold>)</ce:section-title>
                        <ce:para id="p0375" view="all">White solid (yield: 94%). m. p.: 211–213 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.33 (s, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 7.49–7.44 (m, 1H), 7.12 (s, 1H), 6.95 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 3.94 (s, 2H), 3.74 (s, 4H), 3.07 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 161.73, 161.64, 160.86, 158.84, 147.55, 139.40, 138.21, 132.14, 129.95, 122.22, 122.12, 121.31, 117.66, 116.31, 116.14, 101.65, 66.60, 49.45, 27.29; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 415.1888, found 459.1883.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.39" view="all">
                        <ce:label>4.1.39</ce:label>
                        <ce:section-title id="sectitle0305">2-Cyano-N-(3-(6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl) phenyl)acetamide (<ce:bold>22</ce:bold>)</ce:section-title>
                        <ce:para id="p0380" view="all">White solid (yield: 95%). m. p.: 194–195 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.66 (s, 1H), 8.34 (s, 1H), 8.05 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.55 (s, 1H), 7.48 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.08 (s, 1H), 4.14 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 2H), 3.95 (s, 2H), 3.81–3.71 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 161.23, 159.94, 158.54, 138.89, 137.65, 130.40, 129.43, 121.73, 120.77, 117.17, 115.81, 101.05, 60.19, 54.26, 26.79; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">7</ce:inf>NaO<ce:inf loc="post">2</ce:inf> [M+Na]<ce:sup loc="post">+</ce:sup> 386.1348, found 386.1344.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.40" view="all">
                        <ce:label>4.1.40</ce:label>
                        <ce:section-title id="sectitle0310">2-Cyano-N-(2-((3-(6-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl) amino)-2-oxoethyl)acetamide (<ce:bold>23</ce:bold>)</ce:section-title>
                        <ce:para id="p0385" view="all">White solid (yield: 83%). m. p.: 213–214 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.65 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 8.34 (s, 1H), 8.01 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 7.53 (s, 1H), 7.46 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 7.07 (s, 1H), 3.98 (d, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 3.84 (s, 3H), 3.77 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 167.26, 162.79, 160.05, 158.33, 139.22, 137.34, 129.30, 121.35, 120.92, 117.29, 116.08, 101.13, 43.08, 38.72, 25.21; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">8</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 391.1636, found 391.1630.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.41" view="all">
                        <ce:label>4.1.41</ce:label>
                        <ce:section-title id="sectitle0315">2-Cyano-N-(2-((3-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl) amino)-2-oxoethyl)acetamide (<ce:bold>28</ce:bold>)</ce:section-title>
                        <ce:para id="p0390" view="all">White solid (yield: 88%). m. p.: 257–259 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 2H), 8.33 (s, 1H), 7.67 (s, 2H), 7.50 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.48–7.41 (m, 1H), 7.10 (s, 1H), 6.92 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 3.97 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 3.75 (s, 2H), 3.72 (s, 4H), 3.04 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 167.28, 162.81, 161.07, 160.08, 158.06, 147.05, 139.25, 137.24, 131.51, 129.35, 121.61, 121.31, 120.94, 117.20, 116.11, 115.61, 101.13, 66.07, 48.88, 43.05, 25.20; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">25</ce:inf>N<ce:inf loc="post">7</ce:inf>NaO<ce:inf loc="post">3</ce:inf> [M+Na]<ce:sup loc="post">+</ce:sup> 494.1912, found 494.1917.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.42" view="all">
                        <ce:label>4.1.42</ce:label>
                        <ce:section-title id="sectitle0320">2-Cyano-N-(2-((3-(6-((1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)<ce:italic>amino)pyrimidin-</ce:italic>4-yl<ce:italic>)phenyl)amino)-2-oxoethyl)acetamide (</ce:italic>
                           <ce:bold>
                              <ce:italic>29</ce:italic>
                           </ce:bold>
                           <ce:italic>)</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0395" view="all">White solid (yield: 82%). m. p.: 223–224 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.66 (s, 2H), 8.36 (s, 1H), 8.07 (s, 1H), 7.98 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1H), 7.57 (s, 1H), 7.50 (d, <ce:italic>J</ce:italic> = 4.1 Hz, 1H), 7.49–7.45 (m, 1H), 7.10 (s, 1H), 4.76 (s, 2H), 3.97 (d, <ce:italic>J</ce:italic> = 5.5 Hz, 2H), 3.77 (s, 2H), 2.62 (d, <ce:italic>J</ce:italic> = 4.4 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 167.24, 167.16, 162.75, 160.30, 158.48, 150.83, 139.25, 137.56, 131.30, 122.21, 121.31, 120.92, 120.53, 117.37, 116.04, 101.00, 54.34, 43.10, 25.55, 25.19; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">9</ce:inf>O<ce:inf loc="post">3</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 448.1844, found 448.1842.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.43" view="all">
                        <ce:label>4.1.43</ce:label>
                        <ce:section-title id="sectitle0325">2-Cyano-N-(3-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>31</ce:bold>)</ce:section-title>
                        <ce:para id="p0400" view="all">White solid (yield: 94%). m. p.: 217–218 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.61 (s, 1H), 8.50 (d, <ce:italic>J</ce:italic> = 5.0 Hz, 1H), 7.83 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.77 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.68 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.48 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.25 (d, <ce:italic>J</ce:italic> = 4.9 Hz, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 4.08 (s, 2H), 3.77 (s, 4H), 3.10 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.25, 161.28, 160.16, 158.96, 139.09, 137.43, 129.25, 122.29, 121.49, 120.47, 120.15, 117.74, 116.29, 115.92, 107.22, 65.87, 49.74, 26.66; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 415.1880, found 415.1882.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.44" view="all">
                        <ce:label>4.1.44</ce:label>
                        <ce:section-title id="sectitle0330">2-Cyano-N-(4-(6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>33</ce:bold>)</ce:section-title>
                        <ce:para id="p0405" view="all">White solid (yield: 96%). m. p.: 192–194 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 8.01 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 3H), 7.69 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.55 (s, 1H), 7.02 (s, 1H), 4.25 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 3.94 (s, 2H), 3.68 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 3.24 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 161.22, 160.36, 159.98, 158.40, 140.09, 132.27, 130.91, 127.12, 121.82, 121.58, 119.15, 115.71, 99.94, 70.62, 57.90, 51.29, 26.80; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 378.1673, found 378.1676.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.45" view="all">
                        <ce:label>4.1.45</ce:label>
                        <ce:section-title id="sectitle0335">2-Cyano-N-(4-(6-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>35</ce:bold>)</ce:section-title>
                        <ce:para id="p0410" view="all">White solid (yield: 95%). m. p.: 240–241 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.60 (s, 1H), 8.00 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.70 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 7.50 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.08 (s, 1H), 6.92 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 3.94 (s, 2H), 3.72 (s, 4H), 3.04 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 161.26, 161.15, 160.24, 158.25, 147.08, 140.15, 132.36, 131.66, 127.14, 121.77, 119.24, 115.66, 100.29, 66.12, 48.98, 26.83; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 415.1888, found 415.1885.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.46" view="all">
                        <ce:label>4.1.46</ce:label>
                        <ce:section-title id="sectitle0340">2-Cyano-N-(4-(2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acetamide (<ce:bold>37</ce:bold>)</ce:section-title>
                        <ce:para id="p0415" view="all">White solid (yield: 96%).m. p.: 225–228 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.44 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 8.15 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 8.01 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.60 (s, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 4.25 (t, <ce:italic>J</ce:italic> = 4.8 Hz, 2H), 3.96 (s, 2H), 3.69 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.26 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.06, 161.38, 159.76, 158.91, 140.67, 132.19, 130.14, 127.67, 123.15, 120.16, 119.18, 115.77, 106.15, 70.86, 57.98, 51.31, 26.91; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 378.1677, found 378.1679.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.47" view="all">
                        <ce:label>4.1.47</ce:label>
                        <ce:section-title id="sectitle0345">2-Cyano-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-2-yl)phenyl)acetamide (<ce:bold>39</ce:bold>)</ce:section-title>
                        <ce:para id="p0420" view="all">White solid (yield: 95%). m. p.: 267–269 °C. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) δ 8.44 (d, <ce:italic>J</ce:italic> = 5.0 Hz, 1H), 8.14 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.73 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.68 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 7.26 (d, <ce:italic>J</ce:italic> = 5.0 Hz, 1H), 6.92 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 3.96 (s, 2H), 3.73 (s, 4H), 3.03 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) δ 163.27, 161.81, 160.73, 159.17, 146.51, 141.12, 133.50, 132.52, 128.10, 120.67, 119.57, 116.20, 116.11, 107.12, 66.61, 49.76, 27.34; HRMS <ce:italic>m/z</ce:italic> (ESI): calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup> 415.1887, found 415.1880.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0350">Bioactivity</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0355">Mice</ce:section-title>
                        <ce:para id="p0425" view="all">Female BALB/c mice (6–8 weeks) were used for modeling DTH and T cell experiments. Male ICR mice (6–8 weeks, body weight 20–22g) were used in PK studies of compound <ce:bold>12</ce:bold>. Mice were purchased from the laboratory animal center of Beijing Huafukang Biological Technology Co., Ltd, (Beijing, China), and were acclimatized at a controlled temperature of 20–22 °C, and a relative humidity of 50–60% under a 12 h light-dark condition. All animal procedures were approved by the Animal Care and Use Committee of Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC, Beijing, China).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0360">Biochemical assays-JAK enzymatic inhibition assay (cell-free kinase activity assays)</ce:section-title>
                        <ce:para id="p0430" view="all">Cell-free kinase (JAK1, JAK2 JAK3, and TYK2, purchased from Invitrogen (Thermo Fisher Scientific, Waltham, Massachusetts, USA) assays were performed using the HTRF KinEASE-TK (Cisbio Bioassays, Codolet, France) method as previously described [<ce:cross-ref id="crosref0370" refid="bib24">24</ce:cross-ref>]. Compounds were screened at serial dilution in the presence of 2% DMSO with a 5-min pre-incubation of kinase and compounds. All reactions started by the addition of ATP and TK-substrate-biotin, incubations were performed at room temperature for 30 min and quenched with stop solution, containing 25 nM Strep-XL665 and TK Ab-Cryptate. Plates were incubated for 1 h before being read on synergy H1 (Biotek Instruments, Winooski, Vermont, USA) using standard HTRF settings. The half maximal inhibitory concentration (IC<ce:inf loc="post">50</ce:inf>) was calculated by nonlinear regression using GraphPad Prism 8.0 software.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0365">T cell isolation</ce:section-title>
                        <ce:para id="p0435" view="all">T cells were purified from single-cell suspensions of spleen and lymph nodes from male and female mice aged 6–8 weeks by negative selection using biotinylated antibodies directed to CD8a, CD11b, CD11c, CD19, CD24, CD45R/B220, CD49b, CD105, I-A/I-E (MHC-II), TER-119/Erythroid, TCR-γδ (all BioLegend, San Diego, CA,USA) and magnetic Streptavidin Nanobeads (BioLegend).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0370">Cell viability assays</ce:section-title>
                        <ce:para id="p0440" view="all">Resting naive T cells, IL-4-treated activated T cells, and RAW264.7 cells were used to determine the cell viability of compounds using the MTS Assay (Promega, Madison, WI, USA) according to the manufacturer’s guidelines. Briefly, purified T cells were stimulated with Ultra-LEAF™ Purified anti-CD3/Ultra-LEAF™ Purified anti-CD28 Biolegend for 72 h, washed with RPMI 1640 medium (Gibco, Thermo Fisher Scientific), and treated with 10 ng/mL of IL-4 (PeproTech, Rocky Hill, NJ, USA) for 48 h. Purified resting T cells (10<ce:sup loc="post">6</ce:sup> cells/mL), IL-4-treated activated T cells (10<ce:sup loc="post">6</ce:sup> cells/ml), and Raw264.7 cells (5 x 10<ce:sup loc="post">5</ce:sup> cells/mL) were treated with vehicle (0.1% DMSO) alone or 10 μM of different compounds for 72 h. The viability of cells was evaluated using the MTS kit by measuring the absorbance at 490 nm in a microplate reader synergy H1 (Biotek). Values were presented as the percent cell viability relative to the vehicle control.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.5" view="all">
                        <ce:label>4.2.5</ce:label>
                        <ce:section-title id="sectitle0375">T cell proliferation</ce:section-title>
                        <ce:para id="p0445" view="all">T cells were adjusted to 10<ce:sup loc="post">6</ce:sup> cells per mL in complete RPMI1640 medium. Next, cells were exposed to anti-CD3/anti-CD28 or IL-2 (Peprotech) in 96-well culture microtiter plates in triplicate. Complete RPMI1640 medium lacking an-CD3/anti-CD28 or IL-2 was used as the control. Cells were incubated at 37 °C in a humidified, 5% CO<ce:inf loc="post">2</ce:inf> incubator for 72 h. Subsequently, the cell viability was monitored using the MTS assay. Values were transformed to the percent inhibition relative to the vehicle control, and IC<ce:inf loc="post">50</ce:inf> curves were created based on nonlinear regression analysis of the data using GraphPad Prism 8.0 software.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.6" view="all">
                        <ce:label>4.2.6</ce:label>
                        <ce:section-title id="sectitle0380">Western blot analysis</ce:section-title>
                        <ce:para id="p0450" view="all">For cytokine stimulation, purified T cells were pre-activated in 96-well plates coated with anti-CD3 and anti-CD28 for 72 h, harvested, cultured with IL-2 (50 U/mL, Peprotech) for 36 h, then, cultured without IL-2 for 36 h before all experiments.</ce:para>
                        <ce:para id="p0455" view="all">Equal numbers of T cells (10<ce:sup loc="post">6</ce:sup> cells/mL) were incubated at the indicated concentration of compounds in DMSO or DMSO alone (control) for 1 h, then stimulated with either IL-2 (50 ng/mL; Peprotech) or IL-15 (50 ng/mL; Peprotech) for 30 min. After stimulation, cells were lysed in cell lysis buffer containing Phenyl methane sulfonyl fluoride (PMSF), complete protease inhibitors and phosphatase inhibitors (Cell signaling technology, Danvers, MA, USA). Protein lysates were quantified by BCA assay (Thermo Fisher Scientific). Equal amounts of total protein (20 μg) were separated by SDS PAGE, transferred to PVDF membranes, followed by membrane blocking with 5% Bovine Serum Albumin buffer (BSA, Sigma-Aldrich, St, Louis, MO, USA) overnight incubation at 4 °C with Abs recognizing STAT5, anti-phospho-Stat5 Tyr694 (Cell Signaling technology) and followed by secondary horseradish peroxidase (HRP)-conjugated antibodies (Cell Signaling technology). Protein bands were visualized by enhanced chemi luminescence (ECL) reagents from Merck Millipore (Belize, USA) and their intensities were quantified using ImageJ Software (NIH, Bethesda, MD, USA).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.7" view="all">
                        <ce:label>4.2.7</ce:label>
                        <ce:section-title id="sectitle0385">Kinase selectivity profiling</ce:section-title>
                        <ce:para id="p0460" view="all">Selectivity profiling of compound <ce:bold>12</ce:bold> (100 nM) was performed at Thermos Fisher (Invitrogen) by using Select Screen® Kinase Profiling by at the Km concentration of ATP of each kinase.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.8" view="all">
                        <ce:label>4.2.8</ce:label>
                        <ce:section-title id="sectitle0390">Time assay and dissociation kinetics of compound <ce:bold>12</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0465" view="all">Compound <ce:bold>12</ce:bold> and tofacitinib or kinase buffer (positive control) were incubated with recombinant JAK3 for various periods of time (0, 2, 5, 10, 15, 20, 30, 40, and 60 min) before ATP, and the substrate was added to initiate the kinase reaction. The stop reactions were kept constant according to HTRF KinEASE-TK assays. Inhibition rate values were plotted versus incubation time using GraphPad Prism 8.0 software.</ce:para>
                        <ce:para id="p0470" view="all">Dissociation kinetics of compound <ce:bold>12</ce:bold> was measured by incubating 2000 nM JAK3 with inhibitors at their IC<ce:inf loc="post">90</ce:inf> for 30 min. Activity was measured as above after a 1000-fold dilution into reaction buffer at an ATP equivalent to its Km. The corresponding HTRF ratios were measured for various periods of time (0, 1, 2, 8, and 24 h) and were calculated as follows: (Signal 665 nm)/(Signal 620 nm) x10000. The corresponding HTRF ratio values were plotted versus time using GraphPad Prism 8.0 software.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.9" view="all">
                        <ce:label>4.2.9</ce:label>
                        <ce:section-title id="sectitle0395">In vivo pharmacokinetic study</ce:section-title>
                        <ce:para id="p0475" view="all">For <ce:italic>in vivo</ce:italic> pharmacokinetic studies, male ICR mice (n = 6), were fasted overnight and received a single dose (30 mg/kg) of compound <ce:bold>12</ce:bold> (dissolved in 5% DMSO and 95% sodium carboxyl methyl cellulose) by oral gavage, Intravenous administration was given at 10% DMSO in saline (10 mg/kg). Blood samples (50 μL) were obtained from the orbital venous sinus at 0 min, 5 min, 10 min, 20 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, and 48 h after compound administration. The concentration of corresponding compounds in blood was analyzed by LC-MS/MS (8050, Shimadzu, Japan), and pharmacokinetic parameters were processed by DAS 3.0 software using each time point and the concentration of corresponding compounds.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.10" view="all">
                        <ce:label>4.2.10</ce:label>
                        <ce:section-title id="sectitle0400">In vivo efficacy studies</ce:section-title>
                        <ce:para id="p0480" view="all">Animals (n = 5 per group for treated mice and n = 3 for control) were sensitized on the abdomen and subsequently challenged on the pinna with OXZ (E0753, Sigma-Aldrich, St, Louis, MO, USA). Compounds (30 mg/kg, by p.o.) or the positive control (tofacitinib, 30 mg/kg) were administered just prior to and during the challenge phase. The left ear served as an internal control. After the final boost, mice were sacrificed through cervical dislocation, each ear was collected with a cork borer with a diameter of 8 mm and quickly weighed. Then, sections of the right ear were immediately fixed in 10% paraformaldehyde solution for 72 h and HE-staining was performed. Changes in ear weight were calculated as the right ear weight-left ear weight. Ear swelling (%) was calculated by the following formula: Ear swelling (%) = (ear weight-left ear weight)/left ear weight x100%. Spleens were isolated and the spleen index was calculated as organ weight 10 mg (mg) per gram (g) of mouse body weight.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0405">Computational analysis</ce:section-title>
                     <ce:para id="p0485" view="all">For computational analysis, we used the X-ray co-crystal structure of JAK3 in the Protein Data Bank (PDB code: <ce:inter-ref id="intref0015" xlink:href="pdb:4Z16" xlink:type="simple">4Z16</ce:inter-ref>) [<ce:cross-ref id="crosref0375" refid="bib24">24</ce:cross-ref>]. The protein structure for the docking studies was prepared using the Protein Preparation Workflow. All crystallographic waters were removed and chain A was kept. Hybridization states, charges, and angles were assigned in the protein structure with missing bond orders, and hydrogen atoms were added. Docking grids were generated and defined based on the centroid of compound <ce:bold>12</ce:bold> in the ATP binding site incorporating hydrogen-bond constraints to the hinge and hydrophobic regions. Ligands were prepared using Molecular Operating Environment (MOE) software. Energy-minimized conformation of each ligand was used to docking calculation input molecules. In this study, Ligand-Fit and CDOCKER docking programs implemented in MOE software were used [<ce:cross-ref id="crosref0380" refid="bib32">32</ce:cross-ref>]. Other docking parameters were kept at default values. The top-scoring pose was employed for discussions.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0410">Statistics</ce:section-title>
                     <ce:para id="p0490" view="all">Statistical analyses were performed using GraphPad Prism 8.0 software. Results are expressed as the mean ± SEM of at least 3 independent experiments. The differences of multiple comparisons were analyzed using one-way ANOVA, followed by an appropriate post hoc test and <ce:italic>p</ce:italic> value < 0.05 was considered statistically significant.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0415">Declaration of competing interest</ce:section-title>
               <ce:para id="p0495" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0420">Acknowledgments</ce:section-title>
               <ce:para id="p0500" view="all">The authors are grateful to financial supports from <ce:grant-sponsor id="gs4" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gs4">30973607</ce:grant-number>, <ce:grant-number refid="gs4">81172934</ce:grant-number>), “Double First-Class” <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100002857" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">New Drug Development Project of China Pharmaceutical University</ce:grant-sponsor> (<ce:grant-number refid="gs1">CPU2018PZQ15</ce:grant-number>), the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100005089" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Beijing Municipal Natural Science Foundation</ce:grant-sponsor> (<ce:grant-number refid="gs2">7182115</ce:grant-number>), <ce:grant-sponsor id="gs5" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">CAMS Innovation Fund for Medical Science</ce:grant-sponsor> (<ce:grant-number refid="gs5">2017-I2M-3-011</ce:grant-number>) and <ce:grant-sponsor id="gs6" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Drug Innovation Major Project of China, China</ce:grant-sponsor> (No. <ce:grant-number refid="gs6">2018ZX09711001-003-001</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0425">Supplementary data</ce:section-title>
                  <ce:para id="p0505" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S022352342030115X/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0430">Supplementary data</ce:section-title>
                  <ce:para id="p0510" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0020" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112148" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112148</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0435">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gadina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bonelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hasni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kanno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Changelian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laurence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Leukoc. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>499</sb:first-page>
                              <sb:last-page>514</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">M. Gadina, C. Johnson, D. Schwartz, M. Bonelli, S. Hasni, Y. Kanno, P. Changelian, A. Laurence, J.J. O’Shea, Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs, J Leukoc Biol, 104 (2018) 499-514.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mavers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Ruderman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Perlman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Intracellular signal pathways: potential for therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Rheumatol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>378</sb:first-page>
                              <sb:last-page>385</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">M. Mavers, E.M. Ruderman, H. Perlman, Intracellular signal pathways: potential for therapies, Curr. Rheumatol. Rep. 11 (2009) 378-385.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gadina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Schreiber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cytokine signaling in 2002: new surprises in the Jak/Stat pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">O’Shea, J. J.; Gadina, M.; Schreiber, R. D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ghoreschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laurence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Janus kinases in immune cell signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunol. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>228</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>273</sb:first-page>
                              <sb:last-page>287</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">K. Ghoreschi, A. Laurence, J.J. O’Shea, Janus kinases in immune cell signaling, Immunol Rev, 228 (2009) 273-287.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kaur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kalra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kaushal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1074</sb:first-page>
                              <sb:last-page>1086</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">K. Kaur, S. Kalra, S. Kaushal, Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis, Clin. Ther. 36 (2014) 1074-1086.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Malerich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Lam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Fine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Klebansky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Tanga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>D’Andrea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7454</sb:first-page>
                              <sb:last-page>7457</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">J.P. Malerich, J.S. Lam, B. Hart, R.M. Fine, B. Klebansky, M.J. Tanga, A. D’Andrea, Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3, Bioorg. Med. Chem. Lett. 20 (2010) 7454-7457.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Fridman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Scherle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Collins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Burn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Covington</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Collier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Favata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McGee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Haley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shepard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Rodgers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yeleswaram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Newton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Metcalf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Vaddi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>184</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5298</sb:first-page>
                              <sb:last-page>5307</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J.S. Fridman, P.A. Scherle, R. Collins, T.C. Burn, Y. Li, J. Li, M.B. Covington, B. Thomas, P. Collier, M.F. Favata, X. Wen, J. Shi, R. McGee, P.J. Haley, S. Shepard, J.D. Rodgers, S. Yeleswaram, G. Hollis, R.C. Newton, B. Metcalf, S.M. Friedman, K. Vaddi, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050, J. Immunol. 184 (2010) 5298-5307.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Parmentier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Voss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Graff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Argiriadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Camp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Padley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>George</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hyland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rosebraugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wishart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Rheumatol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">J.M. Parmentier, J. Voss, C. Graff, A. Schwartz, M. Argiriadi, M. Friedman, H.S. Camp, R.J. Padley, J.S. George, D. Hyland, M. Rosebraugh, N. Wishart, L. Olson, A.J. Long, In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494), BMC Rheumatol, 2 (2018) 23.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hamaguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Amano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Moritomo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shirakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nakai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nomura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Higashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4971</sb:first-page>
                              <sb:last-page>4983</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">H. Hamaguchi, Y. Amano, A. Moritomo, S. Shirakami, Y. Nakajima, K. Nakai, N. Nomura, M. Ito, Y. Higashi, T. Inoue, Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor, Bioorg. Med. Chem. 26 (2018) 4971-4983.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Changelian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Kent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Magnuson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Rizzuti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Perry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Brissette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>McCurdy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Kudlacz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Conklyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Elliott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Koslov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Strelevitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Whipple</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Munchhof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Doty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Casavant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Blumenkopf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hines</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Lillie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Subramanyam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Shang-Poa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Milici</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Beckius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Moyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Woodworth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Gaweco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Beals</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Littman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zagouras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Magna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Saltarelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Nelms</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Des Etages</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Hayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Kawabata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Finco-Kent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Larson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Si</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Paniagua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Higgins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Holm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Reitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Morris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Borie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>302</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>875</sb:first-page>
                              <sb:last-page>878</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">P.S. Changelian, M.E. Flanagan, D.J. Ball, C.R. Kent, K.S. Magnuson, W.H. Martin, B.J. Rizzuti, P.S. Sawyer, B.D. Perry, W.H. Brissette, S.P. McCurdy, E.M. Kudlacz, M.J. Conklyn, E.A. Elliott, E.R. Koslov, M.B. Fisher, T.J. Strelevitz, K. Yoon, D.A. Whipple, J. Sun, M.J. Munchhof, J.L. Doty, J.M. Casavant, T.A. Blumenkopf, M. Hines, M.F. Brown, B.M. Lillie, C. Subramanyam, C. Shang-Poa, A.J. Milici, G.E. Beckius, J.D. Moyer, C. Su, T.G. Woodworth, A.S. Gaweco, C.R. Beals, B.H. Littman, D.A. Fisher, J.F. Smith, P. Zagouras, H.A. Magna, M.J. Saltarelli, K.S. Johnson, L.F. Nelms, S.G. Des Etages, L.S. Hayes, T.T. Kawabata, D. Finco-Kent, D.L. Baker, M. Larson, M.S. Si, R. Paniagua, J. Higgins, B. Holm, B. Reitz, Y.J. Zhou, R.E. Morris, J.J. O’Shea, D.C. Borie, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor, Science, 302 (2003) 875-878.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="bib11a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ghoreschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Deflorian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Perreira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pesu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Leister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Costanzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8012</sb:first-page>
                              <sb:last-page>8018</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">J.K. Jiang, K. Ghoreschi, F. Deflorian, Z. Chen, M. Perreira, M. Pesu, J. Smith, D.T. Nguyen, E.H. Liu, W. Leister, S. Costanzi, J.J. O’Shea, C.J. Thomas, Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550), J. Med. Chem., 51 (2008) 8012-8018.</ce:source-text>
                     <sb:reference id="bib11b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Bamert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Walden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Wilks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rossjohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Lucet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>219</sb:first-page>
                              <sb:last-page>232</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">N.K. Williams, R.S. Bamert, O. Patel, C. Wang, P.M. Walden, A.F. Wilks, E. Fantino, J. Rossjohn, I.S. Lucet, Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains, J. Mol. Biol., 387 (2009) 219-232.</ce:source-text>
                     <sb:reference id="bib11c">
                        <ce:label>(c)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Hunt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Herrgard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ciceri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Wodicka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pallares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hocker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Treiber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Zarrinkar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comprehensive analysis of kinase inhibitor selectivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1046</sb:first-page>
                              <sb:last-page>1051</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, P.P. Zarrinkar, Comprehensive analysis of kinase inhibitor selectivity, Nat. Biotechnol., 29 (2011) 1046-1051.</ce:source-text>
                     <sb:reference id="bib11d">
                        <ce:label>(d)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Forster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chaikuad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Bauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Holstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Robers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Corona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gehringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pfaffenrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ghoreschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Chem Biol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1335</sb:first-page>
                              <sb:last-page>1340</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">M. Forster, A. Chaikuad, S.M. Bauer, J. Holstein, M.B. Robers, C.R. Corona, M. Gehringer, E. Pfaffenrot, K. Ghoreschi, S. Knapp, S.A. Laufer, Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket, Cell Chem Biol, 23 (2016) 1335-1340.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Klunder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Mittapalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Mohamed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Friedel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Noertersheuser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Othman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-iii clinical trials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Pharmacokinet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1045</sb:first-page>
                              <sb:last-page>1058</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">B. Klunder, R.K. Mittapalli, M.F. Mohamed, A. Friedel, P. Noertersheuser, A.A. Othman, Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials, Clin Pharmacokinet, 58 (2019) 1045-1058.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Biggioggero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Becciolini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Crotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Agape</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.G.</ce:given-name>
                                 <ce:surname>Favalli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drugs Context</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>212595</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">M. Biggioggero, A. Becciolini, C. Crotti, E. Agape, E.G. Favalli, Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis, Drugs Context, 8 (2019) 212595.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Rivellese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lobasso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Barbieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liccardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Paulis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.W.</ce:given-name>
                                 <ce:surname>Rossi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel therapeutic approaches in rheumatoid arthritis: role of Janus kinases inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>16</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2823</sb:first-page>
                              <sb:last-page>2843</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">F. Rivellese, A. Lobasso, L. Barbieri, B. Liccardo, A. de Paulis, FW. Rossi: Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Curr Med Chem. 2019;26(16):2823-2843.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Juba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Czerwinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casimiro-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Balbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Che</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hayward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Montgomery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Soucy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Coe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Langille</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chrencik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d] pyrimidin-4-yl) amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1971</sb:first-page>
                              <sb:last-page>1993</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">A. Thorarensen, M.E. Dowty, M.E. Banker, B. Juba, J. Jussif, T. Lin, F. Vincent, R.M. Czerwinski, A. Casimiro-Garcia, R. Unwalla, J.I. Trujillo, S. Liang, P. Balbo, Y. Che, A.M. Gilbert, M.F. Brown, M. Hayward, J. Montgomery, L. Leung, X. Yang, S. Soucy, M. Hegen, J. Coe, J. Langille, F. Vajdos, J. Chrencik, J.B. Telliez, Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d] pyrimidin-4-yl) amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. J. Med. Chem. 60 (2017) 1971-1993.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Moy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Balbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Crouse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dickinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Symanowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hayward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Montgomery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bauman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casimiro-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Geoghegan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Quazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3442</sb:first-page>
                              <sb:last-page>3451</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">J.B. Telliez, M.E. Dowty, L. Wang, J. Jussif, T. Lin, L. Li, E. Moy, P. Balbo, W. Li, Y. Zhao, K. Crouse, C. Dickinson, P. Symanowicz, M. Hegen, M.E. Banker, F. Vincent, R. Unwalla, S. Liang, A.M. Gilbert, M.F. Brown, M. Hayward, J. Montgomery, X. Yang, J. Bauman, J.I. Trujillo, A. Casimiro-Garcia, F.F. Vajdos, L. Leung, K.F. Geoghegan, A. Quazi, D. Xuan, L. Jones, E. Hett, K. Wright, J.D. Clark, A. Thorarensen, Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition, ACS Chem. Biol. 11 (2016) 3442-3451.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kawamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>McVicar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Johnston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.B.</ce:given-name>
                                 <ce:surname>Blake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Q.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Lal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Lloyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Kelvin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Staples</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ortaldo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>91</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6374</sb:first-page>
                              <sb:last-page>6378</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">M. Kawamura, D.W. McVicar, J.A. Johnston, T.B. Blake, Y.Q. Chen, B.K. Lal, A.R. Lloyd, D.J. Kelvin, J.E. Staples, J.R. Ortaldo, et al., Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes, Proc. Natl. Acad. Sci. U S A, 91 (1994) 6374-6378.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pesu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Borie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Changelian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A new modality for immunosuppression: targeting the JAK/STAT pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>555</sb:first-page>
                              <sb:last-page>564</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">J.J. O’Shea, M. Pesu, D.C. Borie, P.S. Changelian, A new modality for immunosuppression: targeting the JAK/STAT pathway, Nat. Rev. Drug Discov. 3 (2004) 555-564.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Rochman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Spolski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Leonard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New insights into the regulation of T cells by gamma(c) family cytokines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>480</sb:first-page>
                              <sb:last-page>490</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">Y. Rochman, R. Spolski, W.J. Leonard, New insights into the regulation of T cells by gamma(c) family cytokines, Nat Rev Immunol, 9 (2009) 480-490.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Russell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tayebi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Riedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Aman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Migone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Noguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Markert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Buckley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Leonard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>270</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>797</sb:first-page>
                              <sb:last-page>800</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">S.M. Russell, N. Tayebi, H. Nakajima, M.C. Riedy, J.L. Roberts, M.J. Aman, T.S. Migone, M. Noguchi, M.L. Markert, R.H. Buckley, J.J. O’Shea, W.J. Leonard, Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development, Science, 270 (1995) 797-800.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5023</sb:first-page>
                              <sb:last-page>5038</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">J.D. Clark, M.E. Flanagan, J.B. Telliez, Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases, J Med Chem, 57 (2014) 5023-5038.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thareja</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>315</sb:first-page>
                              <sb:last-page>326</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">C. Liang, D. Tian, X. Ren, S. Ding, M. Jia, M. Xin, S. Thareja, The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review, Eur J Med Chem, 151 (2018) 315-326.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Akahane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McNally</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Reyskens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Ficarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Herter-Sprie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Pattison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Labella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Johannessen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Akbay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Marto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Look</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Arthur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of selective covalent Janus kinase 3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6589</sb:first-page>
                              <sb:last-page>6606</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">L. Tan, K. Akahane, R. McNally, K.M. Reyskens, S.B. Ficarro, S. Liu, G.S. Herter-Sprie, S. Koyama, M.J. Pattison, K. Labella, L. Johannessen, E.A. Akbay, K.K. Wong, D.A. Frank, J.A. Marto, T.A. Look, J.S. Arthur, M.J. Eck, N.S. Gray, Development of Selective Covalent Janus Kinase 3 Inhibitors, J Med Chem, 58 (2015) 6589-6606.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1646</sb:first-page>
                              <sb:last-page>1657</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">R.N. Yu, C.J. Chen, L. Shu, Y. Yin, Z.J. Wang, T.T. Zhang, D.Y. Zhang, Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors, Bioorg. Med. Chem. 27 (2019) 1646-1657.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4774</sb:first-page>
                              <sb:last-page>4786</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Y. Yin, C.J. Chen, R.N. Yu, Z.J. Wang, T.T. Zhang, D.Y. Zhang, Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors, Bioorg. Med. Chem. 26 (2018) 4774-4786.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1562</sb:first-page>
                              <sb:last-page>1576</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Y. Yin, C.J. Chen, R.N. Yu, L. Shu, T.T. Zhang, D.Y. Zhang, Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold, Bioorg. Med. Chem. 27 (2019) 1562-1576.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.B.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.N.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617Fagainst myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>49</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">M. Hu, C.B. Xu, C. Yang, H.L. Zuo, C.J. Chen, D. Zhang, G.N. Shi, W.J. Wang, J.G. Shi, T.T. Zhang, Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617Fagainst myeloproliferative neoplasms, J. Exp. Clin. Cancer Res. 38 (2019) 49.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Tyner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Bumm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Aichberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Loriaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5232</sb:first-page>
                              <sb:last-page>5240</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">J.W. Tyner, T.G. Bumm, J. Deininger, L. Wood, K.J. Aichberger, M.M. Loriaux, B.J. Druker, C.J. Burns, E. Fantino, M.W. Deininger, CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms, Blood, 115 (2010) 5232-5240.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>181</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111590</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Y. Li, T. Ye, L. Xu, Y. Dong, Y. Luo, C. Wang, Y. Han, K. Chen, M. Qin, Y. Liu, Y. Zhao, Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3, Eur J Med Chem, 181 (2019) 111590.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nuhaily</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Damaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Maghazachi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oxazolone-induced delayed type hypersensitivity reaction in the adult yucatan pigs. A useful model for drug development and validation, toxins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>25</sb:first-page>
                              <sb:last-page>36</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">S. Nuhaily, B. Damaj, A. Maghazachi, Oxazolone-Induced Delayed Type Hypersensitivity Reaction in the Adult Yucatan Pigs. A Useful Model for Drug Development and Validation, Toxins, 1 (2009) 25-36.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fujii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sengoku</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>91</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>213</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Y. Fujii, T. Sengoku, Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis, Pharmacology, 91 (2013) 207-213.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.N.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer’s disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>168</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>220</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">D.M. Wang, M. Hu, X.P. Li, D. Zhang, C.J. Chen, J.M. Fu, S.A. Shao, G.N. Shi, Y. Zhou, S. Wu, T.T. Zhang, Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer’s disease, Eur. J. Med. Chem. 168 (2019) 207-220.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>